The therapeutic potential of triptolide and celastrol in neurological diseases

Yueran Cui¹, Xuejiao Jiang² and Juan Feng¹*

¹Department of Neurology, Shengjing Hospital of China Medical University, Shenyang, Liaoning, China, ²Department of Otolaryngology Head and Neck Surgery, Shengjing Hospital of China Medical University, Shenyang, Liaoning, China

Neurological diseases are complex diseases affecting the brain and spinal cord, with numerous etiologies and pathogenesis not yet fully elucidated. Tripterygium wilfordii Hook. F. (TWHF) is a traditional Chinese medicine with a long history of medicinal use in China and is widely used to treat autoimmune and inflammatory diseases such as systemic lupus erythematosus and rheumatoid arthritis. With the rapid development of modern technology, the two main bioactive components of TWHF, triptolide and celastrol, have been found to have anti-inflammatory, immunosuppressive and anti-tumor effects and can be used in the treatment of a variety of diseases, including neurological diseases. In this paper, we summarize the preclinical studies of triptolide and celastrol in neurological diseases such as neurodegenerative diseases, brain and spinal cord injury, and epilepsy. In addition, we review the mechanisms of action of triptolide and celastrol in neurological diseases, their toxicity, related derivatives, and nanotechnology-based carrier system.

KEYWORDS
neurological diseases, traditional Chinese medicine, triptolide, celastrol, neuroprotection, toxicity, derivatives

1 Introduction

Neurological diseases are disorders affecting the brain and spinal cord, which are caused by many endogenous and exogenous factors (Mehndiratta and Aggarwal, 2021). These functional or organic disorders cause patients to exhibit many corresponding clinical symptoms, such as dementia, pain and muscle strength disorders, which place a tremendous burden on the patients and society (Borsook, 2012). With the accelerated aging of the population, the incidence of neurological diseases is gradually increasing, and it is becoming a global problem. However, due to the complexity of neurological diseases, the pathogenesis of neurological diseases is not yet clear and effective treatments are limited (Yang et al., 2022a). Studies have shown that many factors are involved in the pathogenesis of neurological diseases (Liu Q. et al., 2022; Delport and Hewer, 2022; Wu et al., 2022). A growing number of studies have suggested that inflammation and immunity play an important role in the development of neurological diseases (Perry et al., 2010; Schiavone and Trabace, 2017; Jiang et al., 2018). Therefore, the investigation of the role of inflammation and immunity in neurological diseases, as well as the related...
therapeutic approaches, may contribute to the effective treatments of neurological diseases.

*Tripterygium wilfordii Hook. F* (TWHF) is a perennial woody vine, which grows mainly in Eastern and Southern China, Japan, and Korea (Brinker et al., 2007). As a classical traditional Chinese medicine, TWHF has a history of over 2,000 years of medicinal use (Li and Hao, 2019). TWHF has a wide range of mechanisms of action and has been used in a variety of diseases, especially autoimmune and inflammatory diseases such as rheumatoid arthritis and dermatomyositis (Wang et al., 2016). Currently, more than 100 components have been extracted from TWHF, of which triptolide and celastrol play an important role in the core bioactivity of TWHF, the anti-inflammatory and antioxidant (Figure 1) (Li and Hao, 2019). Triptolide is an important diterpenoid isolated from TWHF and was first extracted for medicinal research in 1972 (Kupchan et al., 1972). Celastrol is derived from a wide variety of natural plants and accounts for a large percentage of the extracts of the roots of TWHF (Lange et al., 2017). Studies have found that triptolide and celastrol are therapeutically effective in preclinical and clinical studies in a variety of diseases, which may be related to their anti-inflammatory and antioxidant effects (Gao et al., 2021; Schiavone et al., 2021). Because of their small molecular weight and lipophilicity, they can cross the blood-brain barrier and work in the brain, so they have been studied in many neurological diseases (Cleren et al., 2005; Lu et al., 2010; De Angelis et al., 2020), and their roles in neurological diseases are the focus of this review (Table 1).

In this review, we review the progress of research focusing on the therapeutic potential of triptolide and celastrol in neurological diseases, possible mechanisms of action of them, their toxicity and derivatives, and nanotechnology-based carrier system. This will contribute to the further understanding and in-depth studies of the therapeutic potential of these two components.

2 Effects of triptolide and celastrol on neurodegenerative diseases

2.1 Alzheimer’s disease

Alzheimer’s disease (AD) is a common neurodegenerative disease that can lead to symptoms such as dementia and affect people worldwide (Andrieu et al., 2015). The main pathological features of AD include the formation of extracellular pathological plaques (formed by the accumulation of amyloid-beta (Aβ) peptides) and the presence of intracellular neurofibrillar entanglements (formed by aggregations of hyperphosphorylated Tau proteins) (Montine et al., 2012). The etiology of AD is not yet fully understood, and a growing body of research suggests an important role for neuroinflammation in the pathology of AD (Dá Mesquita et al., 2016; Wang et al., 2017; Jiang et al., 2022). For example, studies have found that impairment of synaptic function in AD is associated with increased neuroinflammation (Dá Mesquita et al., 2016). Considering the anti-inflammatory and antioxidant effects of TWHF, many studies have reported the therapeutic effects of bioactive components of TWHF on AD in recent years.

2.1.1 Triptolide

Triptolide is one of the important bioactive components of TWHF and it exerts neuroprotective and neurotrophic effects in AD (Li and Hao, 2019). Moreover, it has a small molecular weight and lipophilicity, which makes it have a better performance in the treatment of AD (Shui et al., 2010). The neuroprotective effects of triptolide on AD have been reported in both *in vivo* and *in vitro* studies. Wan et al. found that triptolide (intraperitoneal injection) could attenuate the degeneration of dendritic spines in hippocampal neurons in AD rats injected with Aβ 1-40 (Wan et al., 2014). Beside that, a study found that in the amyloid precursor protein/presenilin 1 (APP/PS1) double transgenic AD murine model, peripherally administered triptolide improved cognitive function, accompanied by reduced neuroinflammation and Aβ deposition, and that reduction of Aβ deposition may be associated with enhanced Aβ degradation (Cheng et al., 2014). In another study, in the APP/PS1 model of AD, intraperitoneally injected triptolide was found to reduce astrocyte proliferation and microglial activation in the hippocampal region, which was also related to the formation of pathological plaques and neurofibrillary tangles (Li et al., 2016; Villegas-Llerena et al., 2016). Furthermore,
# TABLE 1 Effects of triptolide and celastrol on neurological diseases.

| Disease                     | Component | In vivo/In vitro | Effects                                                                 | References |
|-----------------------------|-----------|------------------|----------------------------------------------------------------------|------------|
| Alzheimer's disease         | Triptolide | in vivo; Aβ 1-40-induced AD rats | attenuates the degeneration of dendritic spines in hippocampal neurons | Wan et al. (2014) |
|                             |           | in vivo; APP/PS1 double transgenic AD murine model | improves cognitive function, accompanied by reduced neuroinflammation and Aβ deposition | Cheng et al. (2014) |
|                             |           | in vivo; APP/PS1 double transgenic AD murine model | reduces astrocyte proliferation and microglia activation in the hippocampal region | Li et al. (2016) |
|                             |           | in vivo; APP/PS1 double transgenic AD murine model | improves spatial memory deficits by inhibiting inflammatory responses and MAPKs activity | Wang et al. (2014) |
|                             |           | in vitro; SH-SY5Y cell lines | exerts neuroprotective effects by inhibiting CXCR2 activity and reducing Aβ production | Wang et al. (2013b) |
|                             |           | in vitro; Aβ 1-42-treated cultured rat microglia | exerts protective effects by inhibiting TNF-α and IL-1β expression levels | Juo et al. (2008) |
|                             |           | in vitro; SH-SY5Y cell lines | inhibits the level of ROS, attenuating apoptosis | He et al., 2003; Gu et al., 2004 |
|                             |           | in vitro; SH-SY5Y cell lines | promotes autophagy and inhibits oxidative stress, exerting neuroprotective effects | Xu et al., 2015; Xu et al., 2016 |
|                             |           | in vitro; Aβ 25-35-treated differentiated PC12 cells | nanoparticle loaded with triptolide reduces oxidative stress and inhibits cytotoxicity | Jia et al. (2021) |
|                             |           | in vitro; Aβ 1-42-treated differentiated PC12 cells | increases synthesis and release of nerve growth factor | Xue et al. (2007) |
|                             |           | in vitro; primary astrocytes from rats | improves the expression of synaptophysin | Nie et al. (2012) |
|                             |           | in vitro; hippocampal neurons | increased hippocampal neuronalin-1 expression through epigenetic mechanisms | Lu et al. (2019) |
|                             |           | in vitro; APP/PS1 double transgenic AD murine model | improves performance in memory and learning activity tests | Allison et al. (2001) |
|                             | Celastrol  | in vivo; LPS rat model | attenuates the accumulation of pathological plaque and microglial activation | Paris et al. (2010) |
|                             |           | in vivo; double transgenic TgPS1/APPsw AD mice | improves cognitive function and decreases amyloid substance | Liao et al. (2018) |
|                             |           | in vivo; diabetes mellitus rat model | improves learning and memory deficits by inhibiting NF-kB activity, improving synaptic function and increasing glucose metabolism | Xiao et al. (2021) |
|                             |           | in vivo; Aβ 25-35-microinjected rats | activates transcription factor EB-mediated autophagy and lysosome biogenesis, reduce the accumulation of neurofibrillary tangles, thereby attenuating disease severity | Yang et al. (2022b) |
|                             |           | In vivo and vitro; P301S microtuble associated protein tau mice and 3XTg mice, N2a cells | inhibits the expression of Hsp90 | Allison et al. (2001) |
|                             |           | in vitro; human monocytes and macrophages, microglia, endothelial cells | attenuates NF-kB activity | Paris et al. (2010) |
|                             |           | in vitro; HEK293 cells | inhibits amyloid-β production by inhibiting BACE-1 | Paris et al. (2010) |
|                             |           | in vitro; 7 W CHO cells overexpressing wild-type human APP | exerts neuroprotective effects by inhibiting IKK | Veerappan et al. (2017) |
|                             |           | in vitro; IMR-32 cells | celastrol inhibits the production of Aβ, attenuates NF-kB activity and suppresses COX-2 expression. In addition, celastrol increases the expression of Hsp70 and Bcl-2 | Zhao et al. (2014) |
|                             |           | in vitro; LPS-treated H4-APP cells | no effect on the expression of Hsp70, while inhibits the expression of Hsp90 | Cao et al. (2018) |
| Parkinson’s disease         | Triptolide | in vivo; LPS rat model |                                                                    | Zhou et al. (2005) |

(Continued on following page)
### TABLE 1 (Continued) Effects of triptolide and celastrol on neurological diseases.

| Disease                  | Component                              | In vivo/In vitro | Effects                                                                                                                                  | References                           |
|--------------------------|----------------------------------------|------------------|------------------------------------------------------------------------------------------------------------------------------------------|--------------------------------------|
| Multiple sclerosis       | Triptolide                             | in vivo, C57 BL/6 mouse EAE model | delays the onset of EAE, attenuates the degree of inflammation and demyelination, improves behavioral deficits, and inhibits NF-κB-DNA binding activity | Wang et al. (2008)                   |
|                          |                                        | in vivo, C57 BL/6 mouse EAE model | LLDT-8, suppresses the severity of EAE by inhibiting T-cell activation                                                                   | Fu et al. (2006)                     |
|                          |                                        | in vivo, SJL/J mouse EAE model   | increases expression levels of Hsp70 and stabilisation of the NF-κB/IκBα complex                                                        | Kirzelstein et al. (2009)            |
|                          |                                        | in vivo, cuprizone-induced toxic model | improves behavioral deficits and attenuates neuroinflammation by inhibiting NF-κB activation and promoting intrinsic myelin repair | Sanadgol et al. (2018)              |
|                          | Celastrol                              | in vivo, relapsing-remitting EAE rat model | reduces the severity of EAE by inhibiting T-cell activation                                                                         | Cui et al. (2022)                    |
TABLE 1 (Continued) Effects of triptolide and celastrol on neurological diseases.

| Disease | Component | In vivo/In vitro | Effects                                                                                                                                                                                                 | References            |
|---------|-----------|-----------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------|
| Huntington’s diseases | Celastrol | in vivo; 3-nitropropionic acid-induced HD rat models | decreases striatal lesion volume, increases the expression of Hsp70 in the striata, and attenuates astrogliosis                                                                                           | Cleren et al. (2005)  |
|          |           | in vitro; cell lines expressing mutant polyglutamine protein | inhibits polyglutamine aggregation by inducing HSF1 and increasing the expression of Hsp70                                                                                                              | Zhang and Sarge, (2007) |
|          |           | in vitro; HdhQ111/Q111 knock-in mouse-derived striatal cell line | inhibits mutant huntingtin aggregation, and reverses the abnormal cellular localization of full-length mutant huntingtin                                                                             | Wang et al. (2005)    |
| Amyotrophic lateral sclerosis | Celastrol | in vivo; G93A SOD1 transgenic ALS mouse model | delays disease onset, improves motor deficits, increases the number of neurons, promotes Hsp70 expression, and reduces TNF-a and iNOS levels                                                            | Kiaei et al. (2005)   |
|          |           | in vitro; staurosporin or H2O2-induced primary motoneurons | activates the heat shock response (i.e. increases Hsp70 expression)                                                                                                                                 | Kalmar and Greensmith, (2009) |
|          |           | in vitro; H2O2-treated G93A SOD1 transfected NSC34 cells | reduces cell death by activating MEK/ERK and PI3K/AKT signaling pathways                                                                                                                                  | Li et al. (2017)      |
| Cerebral ischemia | Triptolide | in vivo; focal cerebral ischemia reperfusion rat model | improves neural function, attenuates neuronal apoptosis, and suppresses infiltration of neutrophils by inhibiting NF-kB activity                                                                 | Wei et al. (2004)      |
|          |           | in vivo; focal cerebral ischemia reperfusion rat model | exerts neuroprotection by inhibiting NF-kB activity and suppressing infiltration of neutrophils                                                                                                          | Jin et al., 2015; Bai et al., 2016a; Bai et al., 2016b |}

(Continued on following page)
TABLE 1 (Continued) Effects of triptolide and celastrol on neurological diseases.

| Disease                  | Component                          | In vivo/In vitro | Effects                                                                                                                                   | References                     |
|--------------------------|------------------------------------|------------------|------------------------------------------------------------------------------------------------------------------------------------------|---------------------------------|
|                          | Triptolide                         |                  |                                                                                                                                           |                                 |
| Traumatic brain injury   | Triptolide                         | in vivo; TBI rat model | improves neurological deficits and attenuates contusion volume, edema, cell apoptosis, decreases expressions of pro-inflammatory cytokines while increases level of anti-inflammatory cytokines | Lee et al. (2012)               |
|                          | Celiastrol                         | in vivo, TBI mouse model | improves neurobehavioral functions and protects neuronal cells by inducing Hsp70/ Hsp110 expression                                          | Eroglu et al. (2014)            |
| Spinal cord injury       | Triptolide                         | in vivo and vitro; SCI rat model and LPS-stimulated primary astrocytes | promotes spinal cord repair, inhibits inflammation, and attenuates astrogliosis and glial scar by inhibiting the JAK2/STAT3 pathway | Su et al. (2010)                |
|                          |                                    | in vivo; SCI rat model | exerts neuroprotection by targeting the miR-96/IKKβ/NF-kB pathway and thus inhibiting microglial activation                                    | Huang et al. (2019)            |
|                          |                                    | in vivo; SCI mouse model | enhances autophagy and inhibits MAPK/ERK1/2 signaling pathway                                                                                 | Zhu et al. (2020)              |
|                          | Celiastrol                         | in vitro; SCI spinal cords model | reduces motorneuron death by inducing Hsp70 expression, while exerts limited protection on the lumbar motor network                          | Petrović et al. (2019)          |
|                          |                                    | in vivo and vitro; SCI rat model and LPS + ATP-induced BV2 cells | attenuates microglial activation in the spinal cord, inhibits the expression of NF-kB, thus inhibiting the expression of NLRP3, caspase-1, GSDMD and inflammatory cytokines, while increases the levels of anti-inflammatory cytokines | Dai et al. (2019)              |
| Epilepsy                 | Triptolide                         | in vivo; kainic acid-induced epilepsy rat model | protects neurons, which is associated with increased expression of neuron kvl.1 in the CA3 region of the hippocampus                                 | Pan et al. (2012)              |
|                          |                                    | in vitro; kainic acid-stimulated BV2 microglia | inhibits microglial activation, decreases MHC II expression in microglia by inhibiting AP-1/class II transactivator, which is related to neuronal death         | Sun et al. (2018)              |
|                          | Celiastrol                         | in vivo; multiple-hit rat model | has a therapeutic effect by inhibiting NF-kB, inhibits NOX activation and rapid H2O2 release, thus alleviating epileptic seizure                | Schiavone et al. (2021)        |
|                          |                                    | in vivo and vitro; kainic acid-induced rats and hippocampal slices | increases microglial activation in hippocampal CA1 and CA3 regions and reduces postkindling seizure thresholds                                  | Malkov et al. (2019)           |
|                          |                                    | in vivo; mouse amygdala-kindling model |                                                                                                | von Rüden et al. (2019)        |
Inhibited cytotoxicity (Jia et al., 2021). The above and inhibition of inflammatory responses and mitogen-activated protein kinase (MAPK)s activity (Cui et al., 2016). In addition, Bakshi et al. reported that knockout of C-X-C chemokine receptor type 2 (CXCR2) inhibited Aβ production in the APP/PS1 model of AD, further elucidating the mechanism of Aβ production in AD (Bakshi et al., 2011). In vitro experiments revealed that in SH-SY5Y cells, triptolide could exert neuroprotective effects by inhibiting CXCR2 activity and reducing Aβ production (Wang et al., 2013b). These suggest that CXCR2 may play an important role in Aβ production. A variety of cells are involved in the development of AD, of which microglia, as important cells in the neuroinflammatory process, were reported in previous studies. Jiao et al. found that in Aβ 1-42-treated cultured rat microglia, triptolide inhibited tumor necrosis factor-α (TNF-α) and interleukin-1β (IL-1β) expression levels and thus exerted neuroprotective effects (Jiao et al., 2008). Furthermore, triptolide was reported to exert neuroprotective effects in neuronal PC12 cells. A previous study suggested that triptolide decreased the level of reactive oxygen species (ROS), thus attenuating apoptosis in PC12 cells stimulated by glutamate (He et al., 2003). In consistence with this, Gu et al. also found the attenuation of triptolide on apoptosis of PC12 cells (Gu et al., 2004). Beside that, Xu et al. demonstrated the neuroprotective effects of triptolide in Aβ 25-35-treated differentiated PC12 cells, which involves autophagy pathway and inhibition of oxidative stress (Xu et al., 2015; Xu et al., 2016). In view of the clinical use of triptolide, a recent study used nanoparticles loaded with triptolide to treat Aβ 1-42-treated differentiated PC12 cells and showed that this treatment reduced oxidative stress and consequently significantly inhibited cytotoxicity (Jia et al., 2021). The above experimental studies have shown that triptolide exerts neuroprotective effects in AD, which provides a theoretical basis for its clinical application.

In addition to neuroprotective effects, the neurotrophic effects of triptolide in AD has also been studied. It was found that primary astrocytes from rats treated with triptolide showed increased synthesis and release of nerve growth factor (NGF), a key neurotrophic factor that is essential for nerve cells (Xue et al., 2007). Moreover, in a cellular model of AD, treatment with triptolide increased the expression of synaptophysin in hippocampal neurons (Nie et al., 2012). Synaptophysin is an important protein of synaptic vesicle membrane and is mainly expressed at the presynaptic endings of the nervous system (Garcia-Mesa et al., 2022). Recently, a study reported that intraperitoneally injected triptolide increased hippocampal ne ulcerin-1 (a cell adhesion protein, located on the excitatory postsynaptic membrane) expression in the APP/PS1 model of AD through epigenetic mechanisms (Lu et al., 2019). These studies demonstrate the neurotrophic effects of triptolide on AD models.

Above data suggest that triptolide exerts therapeutic effects on AD by the following mechanisms: 1) inhibiting Aβ deposition by inhibiting BACE1 or CXCR2 in neurons, 2) inhibiting MAPKs activity and attenuating neuroinflammation in microglia, 3) decreasing level of ROS and inhibiting oxidative stress in neurons, 4) attenuating apoptosis and stabilizing mitochondrial membrane potential in neurons, 5) enhancing autophagy in neurons, 6) exerting neurotrophic effects by promoting expression of NGF (in astrocytes), synaptophysin (in neurons), and neulroligin-1.

2.1.2 Celastrol

Celastrol, one of the important bioactive components extracted from TWHF, has been the subject of many studies for the treatment of AD. Allison et al. reported that lipopolysaccharide (LPS) rat model intraperitoneally administered with celastrol exhibited improved performance in memory and learning activity tests (Allison et al., 2001). Moreover, subcutaneous treatment with celastrol was found to attenuate the accumulation of pathological plaque and microglial activation in the double transgenic Tg PS1/APPsw (human APP695sw mutation and the presenilin-1 mutation M146L) AD mice (Paris et al., 2010). In addition, the diabetes mellitus rat model showed reduced cognitive function and increased amyloid substance, similar to the alterations shown in the AD model, and celastrol treatment (intraperitoneal injection) inhibited these alterations (Liao et al., 2018). Recently, a study found that intraperitoneally administered celastrol improved learning and memory deficits in Aβ 25-35-microinjected rats (Xiao et al., 2021). Further, this study suggests that the neuroprotective effect of celastrol is associated with inhibition of nuclear factor-kappaB (NF-kB) activity, improved synaptic function and increased glucose metabolism. A recent study proposed that celastrol mixed in regular feed could reduce the accumulation of neurofibrillary tangles in the brains of two common animal models of AD (P301S microtubule associated protein tau mice and 3XTg mice) by activating transcription factor EB-mediated autophagy and lysosome biogenesis, thereby attenuating memory deficits in AD mice. Similarly, these effects of celastrol were also found in N2a cells (Yang et al., 2022b).

Beside that, other related in vitro experiments have further explored the possible mechanisms involved in the neuroprotective effects of celastrol on AD. Low doses of celastrol have been reported to inhibit the production of TNF-α and IL-1β by human monocytes and macrophages, the expression of major histocompatibility complex II (MHC II) molecules of microglia, and the production of inducible nitric oxide synthase (iNOS) in endothelial cells (Allison et al., 2001). It is well known that NF-kB is an important regulator in inflammatory responses. Paris et al. found that celastrol could attenuate NF-kB activity in HEK293 cells; moreover, they also
demonstrated the inhibition of celastrol on Aβ production in 7 W CHO cells overexpressing wild-type human APP, which is related to the inhibition of BACE-1 (β-site APP cleaving enzyme) (Paris et al., 2010). BACE-1 is a major β-secretase, exerting effects on proteolysis of the β-APP to obtain Aβ peptides (Vassar et al., 1999). Furthermore, using molecular docking and in vitro assays, a study found that celastrol exerts neuroprotective effects in IMR-32 cells by inhibiting inhibitor κB kinase (IKK), which is the converging point in the activation of NF-κB (Veerappan et al., 2017). Moreover, it was reported that celastrol inhibited the production of Aβ in LPS-treated H4-APP cells, attenuated NF-κB activity and suppressed cyclooxygenase-2 (COX-2) expression. In addition, the effects of celastrol on increased levels of heat shock protein (Hsp) 70 and Bcl-2 expression have been reported (Zhao et al., 2014). Heat shock proteins are a series of proteins that have effects on folding of proteins. Among them, Hsp27 and Hsp70 are thought to have neuroprotective effects and their low levels are associated with AD (Chow et al., 2014). It was found that celastrol induced the increase in the expression of Hsp27 and Hsp70 in mature brain cortical cultures (Chow et al., 2013). However, in another study, celastrol was found to have no effect on the expression of Hsp70 in Aβ 1-42-treated SH-SY5Y cells, but could inhibit the expression of Hsp90 (Cao et al., 2018). This suggests that celastrol can exert neuroprotective effects through different pathways.

These studies reveal the mechanisms of therapeutic effects of celastrol on AD: 1) inhibiting NF-κB activity and attenuating neuroinflammation in microglia and neurons, 2) reducing accumulation of neurofibrillary tangles by activating transcription factor EB-mediated autophagy and lysosome biogenesis, 3) inhibiting Aβ production by inhibition of BACE-1 in neurons, 4) increasing the expression of Hsp70 in mature brain cortical cultures while decreasing the expression of Hsp90 in neurons.

2.2 Parkinson’s disease

Parkinson’s disease (PD), a movement disorder, is the second most common neurodegenerative disease worldwide, mainly affecting older people (Kalia and Lang, 2016). Its main pathological feature is the progressive loss of dopaminergic neurons in the substantia nigra (Dauer and Przedborski, 2003). The main clinical manifestations of PD are resting tremor, bradykinesia, rigidity and postural abnormalities (Postuma et al., 2015). In addition, non-motor symptoms such as autonomic abnormalities, olfactory impairment and cognitive deficits also play an important role in the diagnosis of PD (Martinez-Martín et al., 2011). The pathogenesis of PD is not yet fully understood. Studies have shown that α-synuclein transmission is important in the pathogenesis of PD, which has made α-synuclein a hot topic in the field of PD research in recent years (Kurowska et al., 2011; Ganguly et al., 2022). Moreover, research on neuroinflammation in the pathogenesis of PD has also received widespread attention (Jenner and Olanow, 2006; Arena et al., 2022). As mentioned earlier, TWHF has anti-inflammatory properties. In recent years, there are many studies on the therapeutic effects of its extracts on PD.

2.2.1 Triptolide

Triptolide, as one of the main bioactive components of TWHF exerting anti-inflammatory effects, has been the subject of many in vivo and in vitro studies for its therapeutic effects on PD. Zhou et al. developed an inflammatory rat model by LPS intranigral injection and investigated the therapeutic effects of triptolide by intraperitoneal treatment with triptolide for 24 consecutive days. The results showed that triptolide treatment protected dopaminergic neurons and reduced the expression of pro-inflammatory cytokines, such as TNF-α and IL-1β, thereby exerting neuroprotective effects (Zhou et al., 2005). In line with this, in another inflammatory rat model using LPS induction, triptolide treatment protected dopaminergic neurons and inhibited microglial activation (Li G. et al., 2006). Moreover, a study investigated the neuroprotective effects of triptolide in hemiparkinsonian rats using a 1-methyl-4-phenyl pyridinium (MPP+) -induced rat model. They found that intraperitoneally injected triptolide improved behavioral performance in this model and which may be associated with protection of dopaminergic neurons and inhibition of microglial activation (Gao et al., 2008).

Similar results have been reported in vitro experiments. In primary mesencephalic neuron/glia mixed culture, Li et al. reported the inhibition of triptolide on the decrease in [3H] dopamine uptake and loss of tyrosine hydroxylase-immunoreactive neurons induced by LPS, and underlying mechanism may be related to the inhibition of microglial activation (Li et al., 2004). In this study, they also found that treatment with triptolide inhibited the overproduction of TNF-α and NO. In addition, a study also found that triptolide inhibited TNF-α and NO production in primary microglial cultures (Zhou et al., 2003). Furthermore, a research used a novel extraction method to obtain extracts from TWHF and found that the extracts protected dopaminergic neurons in rat mesencephalic neuron-glia cultures induced by LPS, inhibited microglial activation and TNF-α and NO expression (Liu et al., 2010). Most of the triptolide in the extracts obtained by this new extraction method was converted to tripchlorolide, an analogue of triptolide (Li B. et al., 2006). The therapeutic effects of tripchlorolide on PD are currently being studied in vitro and in vivo. For example, tripchlorolide was found to exert neuroprotective and neurotrophic effects on dopaminergic neurons by promoting axonal elongation and protecting dopaminergic neurons, as well as increasing brain-derived neurotrophic factor (BDNF) mRNA expression (Li et al., 2003). In another study, tripchlorolide was reported to protect
dopaminergic neurons, inhibit the overproduction of TNF-α and IL-2, and thus exerting neuroprotective effects in rat models of PD (Cheng et al., 2002). Beside that, in a mouse model of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-induced PD, intraperitoneally treated with tripchlorolide improved behavioral performance, protected dopaminergic neurons and inhibited astroglial responses, thereby exerting neuroprotective effects (Hong et al., 2007). Recently, it has been shown that the inhibitory effect of tripotolide on mitochondrial activation during PD treatment may be achieved by targeting the microRNA155–5p/SHIP1 pathway or by upregulating metabotropic glutamate receptor 5 (intraperitoneal injection) (Huang et al., 2018; Feng et al., 2019). In addition, enhanced autophagy in neurons, which in turn promotes the clearance of α-synuclein, is one of the possible mechanisms of tripotolide to treat PD (Hu et al., 2017).

The above studies illustrate the therapeutic effects of tripotolide and tripchlorolide on PD models, which is associated with the following mechanisms: 1) attenuating neuron inflammation in microglia and neurons, 2) promoting the clearance of α-synuclein in neurons by enhancing autophagy, 3) exerting neurotrophic effects by increasing the expression of BDNF mRNA in neurons. These suggest that tripotolide and tripchlorolide may be potential candidates for clinical treatment of PD.

2.2.2 Celastrol

Considering the anti-inflammatory effects of celastrol, there are many studies focusing on its therapeutic effects on PD. Faust et al. reported that in the Drosophila DJ-1A model of PD, celastrol inhibited the reduction of dopaminergic neurons and increased brain dopamine content, thereby exerting neuroprotective effects in the PD model (Faust et al., 2009). Beside that, the therapeutic effects of celastrol have also been reported in mouse models of MPTP-induced PD. A previous study reported that intraperitoneally treated with celastrol attenuated the loss of dopaminergic neurons, increased Hsp70 within dopaminergic neurons, and decreased the levels of NF-kB and TNF-α (Cleren et al., 2005). Furthermore, a recent study suggested that the neuroprotective effects of celastrol (intraperitoneal injection) on MPTP-induced PD mouse models was associated with activation of mitophagy (Lin et al., 2019). However, Zhang et al. reported some contradictory results when they found that celastrol inhibited PTEN-induced kinase 1 (PINK1)-dependent mitophagy (Zhang et al., 2019). This may be due to the complicated mechanisms of action of celastrol. Moreover, the therapeutic mechanisms of celastrol has been further explored. Using the adeno-associated virus (AAV)-mediated human α-synuclein overexpression PD model and the MPTP-induced PD mouse model, a team of researchers found that intraperitoneally injected with celastrol can improve motor deficits and thus exert neuroprotective effects by modulating the nuclear factor-erythroid 2-related factor 2 (Nrf2)-Nod-like receptor family, pyrin-domain-containing 3 (NLRP3)-caspase-1 pathway (Zhang et al., 2021). However, a study found that celastrol (intraperitoneal treatment) did not exert neuroprotective effects in Wistar rats in the presence of lactacystin-induced ubiquitin-proteasome system (UPS) inhibition (Koniczny et al., 2014). Consistent with this, celastrol also did not exert neuroprotective effects in SH-SY5Y cells and mouse primary cortical neurons, which incubated with lactacystin. Moreover, the therapeutic effects of celastrol can be found in the rotenone-induced SH-SY5Y model of PD. For example, Deng et al. reported the protection of celastrol on rotenone-induced SH-SY5Y, involving the induction of autophagy (Deng et al., 2013). Further study suggests that this protective effect may also involve preservation of mitochondrial function and inhibition of p38 MAPK (Choi et al., 2014). Recently, a study focused on the role of celastrol on dendritic cells (DCs), and the results demonstrated that celastrol could mediate antigen trafficking in DCs, thus attenuating α-synuclein-specific T cell responses (Ng et al., 2022), and this may be beneficial to the treatment of PD.

These data suggest that mechanisms of therapeutic effects of celastrol on PD: 1) increasing the expression of Hsp70 in neurons, 2) attenuating neuroinflammation, 3) activating mitophagy, 4) inducing autophagy in neurons, 5) preserving mitochondrial function and inhibiting p38 MAPK, 6) mediating antigen trafficking in DCs, thus attenuating α-synuclein-specific T cell responses.

2.3 Multiple sclerosis

Multiple sclerosis (MS) is a demyelinating, neurodegenerative disease that occurs mainly in women. Its main pathological features are early demyelination and late neurodegeneration (Dobson and Giovannoni, 2019). The pathogenesis of MS is not well understood, while it is generally regarded as an autoimmune disease in which autoimmunity and neuroinflammation play a critical role (Segal, 2019). There is currently no cure for MS, and many studies have investigated the therapeutic effects of extracts of triptolide and its analogues can exert neuroprotective effects against EAE. For example, a previous study reported the neuroprotective effects of triptolide on EAE models of C57 BL/6 mice, and results showed that intraperitoneally treated with triptolide could delay the onset of EAE, attenuate the degree of
inflammation and demyelination, and improve behavioral deficits; moreover, the inhibition of NF-κB-DNA binding activity was also found (Wang et al., 2008). In addition, Fu et al. found that intraperitoneally injected with (5R)-5-hydroxytriptolide (LLDT-8), one of the derivatives of triptolide, could suppress the severity of EAE models of C57 BL/6 mice by inhibiting T-cell activation (Fu et al., 2006). The therapeutic effects of triptolide (oral administration) was also found in the EAE model of SJL/J mice, involving increased expression levels of Hsp70 and stabilization of the NF-κB/inhibitor-kappa-B alpha (IkBa) complex (Kizelsztein et al., 2009). In addition to the EAE model, there is also a cuprizone induced toxic model that can be used to study MS, which is primarily used to study damage to oligodendrocytes and myelin sheaths during MS (Abakumova et al., 2015). A recent study demonstrated that, in cuprizone induced toxic models, triptolide administered intraperitoneally improved behavioral deficits and attenuated neuroinflammation by inhibiting NF-κB activation and promoting intrinsic myelin repair (Sanadogel et al., 2018). Together, these related studies demonstrate that inhibiting NF-κB activity and attenuating neuroinflammation are crucial in therapeutic effects of triptolide on MS.

### 2.3.2 Celastrol

There are also basic studies on the therapeutic effects of celastrol on MS. It was shown that in a relapsing-remitting EAE rat model, celastrol (intraperitoneal injection) inhibited relapses and reduced clinical scores by modulating the Th1/Th2 cytokines profile (increased IL-10 expression while reduced TNF-α expression), inhibiting NF-κB and Toll-like receptor 2 (TLR2) expression, and reducing CD3+ T lymphocytic count (O’Brien et al., 2001; Abdin and Hasby, 2014). MS is a classic autoimmune disease in which the imbalance between Th17 and Treg cells is important in the pathophysiology, as evidenced by the promotion of pathological Th17 responses, and the inhibition of Treg responses (Holmay, 2008; Di Mitri et al., 2015). Therefore, several studies have further investigated the effects of celastrol on T cells in EAE. For example, Wang et al. reported that intraperitoneally treated with celastrol exerted neuroprotective effects on EAE by inhibiting Th17 cell responses and attenuating cytokine production in bone-marrow derived dendritic cells (Wang et al., 2015). Moreover, another study suggested that the effect of celastrol (intraperitoneal treatment) on T-cell responses is mediated through the MAPK pathway, in which serum/glucocorticoid regulated kinase 1 (SGK1) expression is suppressed, yet BDNF expression is increased (Venkatesha and Moudgil, 2019). In addition, a study using an EAE rat model found that intraperitoneally injected with celastrol inhibited the expression of iNOS and NF-κB and attenuated MS and optic neuritis in the models (Yang et al., 2017). Similar to triptolide, NF-κB is also a key signaling pathway in therapeutic effects of celastrol on MS. Besides that, celastrol can modulate Th1/Th2 cytokines profile and inhibit Th17 cell responses through the MAPK pathway, thus attenuating neuroinflammation.

### 2.4 Huntington’s diseases and amyotrophic lateral sclerosis

Huntington’s diseases (HD) is a fatal, progressive neurodegenerative disease. It is caused by excessively expanded CAG repeats in the gene and is an autosomal dominant disorder (Rai et al., 2019). Clinical manifestations of HD include motor dysfunction, cognitive impairment and psychiatric disturbances (Ross and Tabrizi, 2011). Currently, HD cannot be completely cured. Some studies have found that celastrol has therapeutic effects on HD, but there are no reports of triptolide in HD. Cleren et al. reported the neuroprotection of celastrol (intraperitoneal injection) on 3-nitropropionic acid-induced HD rat models, and they found that celastrol could decrease striatal lesion volume, increase the expression of Hsp70 in the striata, and attenuate astrogliosis (Cleren et al., 2005). Considering the neuroprotective effects of heat shock proteins and the previously mentioned relationship between celastrol and heat shock proteins, another study explored the therapeutic effects of celastrol and its effect on the heat shock response in cellular models of HD. The results showed that celastrol could inhibit polyglutamine aggregation by inducing heat shock factor 1 (HSF1) and then increasing the expression of Hsp70 (Zhang and Sarge, 2007). In addition, a study used a HdhQ111/Q111 knock-in mouse-derived striatal cell line to investigate the effects of celastrol and found that celastrol inhibited mutant huntingtin aggregation, and reversed the abnormal cellular localization of full-length mutant huntingtin (Wang et al., 2005).

Amyotrophic lateral sclerosis (ALS), a neurodegenerative disease, is an common adult motor neuron disease that can lead to progressive muscle atrophy and even death. Although the pathogenesis of ALS has not been fully elucidated, many studies have shown that the genetic component plays an important role in its development. Current treatment for ALS is mainly symptomatic, while there are some basic studies showing the therapeutic effects of celastrol in ALS models. As with HD, the therapeutic effect of triptolide in ALS has not been reported. A study using celastrol in a G93A-superoxide dismutase 1 (SOD1) transgenic mouse model of ALS found that orally administrated celastrol delayed disease onset, improved motor deficits, and increased the number of neurons, promoted Hsp70 expression, and reduced TNF-α and iNOS levels in the spinal cord (Kiaei et al., 2005). In addition, celastrol was found in vitro experiments to exert neuroprotective effects in primary motoneurons induced by staurosporin or H₂O₂ by activating the heat shock response.
SOD1 transfected NSC34 cells as a cellular model of ALS and exist. Although other mechanisms such as inhibition of astrogliosis, ALS are closely related to heat shock proteins, especially Hsp70, pathways (Li et al., 2017). Kinase (PI3K)/serine-threonine kinase (AKT) signaling of mitogen-activated protein kinase (MEK)/extracellular regulated protein kinases (ERK) and phosphoinositide 3-kinase (PI3K)/serine-threonine kinase (AKT) signaling pathways (Li et al., 2017).

In conclusion, the therapeutic effects of celastrol in HD and ALS are closely related to heat shock proteins, especially Hsp70, although other mechanisms such as inhibition of astrogliosis exist.

3 Effects of triptolide and celastrol on brain and spinal cord injury

3.1 Cerebral ischemia

With an ageing population, the incidence of stroke is increasing, placing a huge burden on society and families. Of these, ischemic stroke is the most common type of stroke and is the third leading cause of disability worldwide (Benjamin et al., 2018; Meng et al., 2021). The therapeutic time window for ischemic stroke is narrow and there are significant financial and care costs for the treatment and rehabilitation of patients with ischemic stroke, so it is important that patients suffering with ischemic stroke are treated promptly and effectively (Sun et al., 2020). Currently, the main treatment options for ischemic stroke episodes include chemical thrombolysis (intravenous) and mechanical thrombectomy (intra-arterial) (Moussaddy et al., 2018). However, these treatments lead to a classic pathophysiological process known as ischemia/reperfusion injury. During cerebral ischemia/reperfusion injury, multiple pathophysiological mechanisms are involved and interact with each other, including oxidative stress, inflammatory responses, neuronal apoptosis and autophagy (Meng et al., 2021). Therefore, many studies have used models of cerebral ischemia/reperfusion injury to conduct research related to cerebral ischemia.

3.1.1 Triptolide

Middle cerebral artery occlusion (MCAO) is a common animal model of cerebral ischemia, and many studies have demonstrated the therapeutic effects of triptolide on MCAO. For example, Wei et al. found that triptolide improved neural function, attenuated neuronal apoptosis, and suppressed infiltration of neutrophils in rat with focal ischemia/reperfusion (Wei et al., 2004). Moreover, since inflammatory responses play an important role in cerebral ischemia/reperfusion injury, several studies further explored the effect of triptolide on NF-kB, an essential regulator of inflammatory responses, in MCAO, and reported the inhibitory effect of triptolide on NF-kB activity (Jin et al., 2015; Bai et al., 2016a; Bai et al., 2016b). In addition, Zhang et al. found that triptolide inhibited NF-kBp53 upregulated modulator of apoptosis (PUMA) signaling pathway, which in turn exerts neuroprotective effects against MCAO (Zhang et al., 2016). This inhibition has also been reported in cellular models. A previous study, using MCAO rats and oxygen-glucose deprivation (OGD) SH-SY5Y cells, found that triptolide inhibited NF-kB and p38 MAPK signaling pathways to exert neuroprotection (Hao et al., 2015). In addition to its effects on NF-kB activity, there are several studies showing that triptolide exerts protective effects against cerebral ischemia by affecting autophagy. For example, Yang et al. found the upregulation of autophagy and downregulation of apoptosis in MCAO treated with triptolide (Yang et al., 2015). In a further study, the team found that the downregulation of apoptosis by triptolide in MCAO was through activation of the PI3K/AKT/mammalian target of rapamycin (mTOR) signaling pathway (Li et al., 2015). Beside that, neurobehavioral function in MCAO was improved by the combined use of the colony-stimulating factor 1 receptor inhibitor and triptolide, involving mechanisms including activation of autophagy and BDNF-AKT signaling pathways (Du et al., 2020). Pan et al. also reported the therapeutic effects of triptolide on MCAO. In their experimental results, triptolide could improve neurobehavioral scores, reduce brain damage, exert anti-inflammatory and antioxidant effects (reduce levels of malondialdehyde (MDA) and ROS, increase superoxide dismutase (SOD) level), and these effects were associated with inhibition of Wnt/β-catenin signaling pathway (Pan and Xu, 2020). In addition, right unilateral common carotid artery occlusion (rUCCAO), which simulates chronic cerebral hypoperfusion, can also be used for cerebral ischemia related research (Yoshizaki et al., 2008). A recent study using rUCCAO and OGD reported the therapeutic effects of triptolide in vitro and in vivo, including alleviating white matter injury, protecting against oligodendrocyte apoptosis directly, and inhibiting microglial inflammation indirectly, and the related mechanism was to increase the phosphorylation of the Src/AKT/GSK3β signaling pathway (Wan et al., 2022).

Take together, triptolide exerts neuroprotective effects on cerebral ischemia by the following mechanisms: 1) inhibiting NF-kB signaling pathway, involving inhibition of NF-kB/PUMA signaling pathway and inhibition of p38 MAPK/NF-kB signaling pathway, 2) enhancing autophagy, 3) inhibiting apoptosis by activating PI3K/AKT/mTOR signaling pathway, 4) upregulating BDNF-AKT signaling pathways, 5) exerting antioxidant effects by inhibiting Wnt/β-catenin signaling pathway, 6) inhibiting oligodendrocyte apoptosis by upregulating the phosphorylation of the Src/AKT/GSK3β pathway.

3.1.2 Celastrol

Many studies have also demonstrated the therapeutic effects of celastrol on cerebral ischemia and related mechanisms. To
study the therapeutic effects of celastrol on cerebral ischemia, Li et al. used a permanent middle cerebral artery occlusion (pMCAO) model (Li et al., 2012). It is worth noting that the process of pMCAO does not involve reperfusion, that is, it does not belong to the ischemia/reperfusion injury model, while it is also an important model for cerebral ischemia research. Their results indicated that celastrol improved neurological function and reduced infarct volume in pMCAO possibly through suppressing the expression of NF-κB, p-c-Jun, and p-(c-Jun N-terminal kinase) JNK. In another study, the transient global cerebral ischemia reperfusion (tGCI/R) model was used, and the investigators obtained similar neuroprotective effects as in the previous pMCAO study. The investigators also found that celastrol could suppress the expression of pro-inflammatory cytokines and MDA and elevate the levels of glutathione (GSH) and SOD in tGCI/R. Moreover, these protective effects of celastrol could be mediated by inhibition of high mobility group protein 1 (HMGB1)/NF-κB signaling pathway (Zhang et al., 2020). Further studies investigated the association between celastrol and HMGB1/NF-κB. Liu et al. found that under conditions of MCAO or OGD, celastrol could directly bind to HMGB1 and in turn inhibit the binding of HMGB1 to its downstream inflammatory components; moreover, celastrol could also target NF-κB and inhibit its activity (Liu D. D. et al., 2021). As important immune cells, microglia/macrophages play an important role in regulating inflammatory response and are involved in the pathophysiology of cerebral ischemia (Hu et al., 2012). Studies have shown that microglia/macrophages have different phenotypes, with M1 microglia releasing neurotoxic substances that exacerbate brain damage, and M2 microglia exerting neuroprotective effects by producing neurotrophic substances and removing debris (Brifault et al., 2015). A study reported neuroprotective effects of celastrol in MCAO and further found in OGD that this neuroprotection was through an IL-33/ST2 axis-mediated M2 microglia/macrophage polarization (Jiang et al., 2018). In addition, glycolysis plays a role in the pathogenesis of cerebral ischemia, and some studies have found that inhibition of excessive glycolysis can protect neurons against OGD (Brifault et al., 2015; Vojinovic et al., 2020). Chen et al. reported that celastrol inhibited hypoxia inducible factor-1α (HIF-1α)/pyruvate dehydrogenase kinase1 (PDK1), thus attenuating glycolysis and exerting neuroprotection (Chen et al., 2022). Besides that, studies of long noncoding RNAs (LncRNAs) have received much attention in recent years. A recent study focused on the role of LncRNAs-AK005401 in the treatment of MCAO with celastrol, and showed that celastrol exerts neuroprotective effects through inhibition of AK005401/MAP3K12 and activation of PI3K/AKT (Wang et al., 2021). In another study, researchers analyzed the profiles of LncRNAs and mRNAs following celastrol treatment of MCAO by RNA-sequencing and bioinformatic analysis and experimentally verified the significantly different LncRNAs and mRNAs (Liu J. et al., 2022). Liu et al. used ultra-performance liquid chromatography-tandem mass spectrometry (UPLC/MS) to perform lipidomic analysis after celastrol treatment of MCAO and obtained some differentially expressed components (Liu M. et al., 2021). These studies have provided a theoretical basis for subsequent in-depth investigations.

Above studies suggest the mechanisms of therapeutic effects of celastrol on cerebral ischemia: a). attenuating neuroinflammation by inhibiting HMGB1/NF-κB signaling pathway, inhibiting the phosphorylation of the JNK, or promoting an IL-33/ST2 axis-mediated M2 microglia/macrophage polarization; b). suppressing glycolysis by inhibiting HIF-1α/PDK1; c). inhibiting AK005401/MAP3K12 and activating PI3K/AKT signaling pathway.

### 3.2 Traumatic brain injury and spinal cord injury

Traumatic brain injury (TBI) is a type of brain trauma that can lead to long-term disability and possibly secondary neurodegenerative disorders (Sivanandam and Thakur, 2012; Humphreys et al., 2013). The role of neuroinflammation in the pathophysiology of TBI cannot be ignored. Numerous studies have reported the damaging effects of neuroinflammation on brain cells in TBI (Kunz et al., 2002; Strauss, 2008). The two main bioactive components of TWHF, triptolide and celastrol, have been reported to have anti-inflammatory and therapeutic effects in models of TBI. For example, a study found that triptolide improved neurological deficits and attenuated contusion volume, edema, and cell apoptosis in TBI-induced brains. Moreover, it also reported the decreased expressions of pro-inflammatory cytokines while the increased level of anti-inflammatory cytokines (Lee et al., 2012). In addition, celastrol was also found to improve neurobehavioral functions and protect neurons in TBI, and the relevant mechanisms involved the induction of Hsp70/Hsp110 expression (Eroglu et al., 2014).

Spinal cord injury (SCI) is also a neurological disease that can lead to long-term disability, with a high mortality and varying clinical symptoms depending on the degree of lesions (Coyoy-Salgado et al., 2019). In terms of pathology, SCI can be divided into primary, secondary and chronic phases, with oxidative stress and inflammation playing an important role in the pathophysiology of it (Fehlings and Tator, 1995; McDonald and Sadowsky, 2002). Su et al. showed that triptolide could promote spinal cord repair in SCI by attenuating astroglisis and inflammation, and that attenuation of astroglisis is via inhibition of the Janus kinase 2 (JAK2)/signal transducer and activator of transcription 3 (STAT3) pathway (Su et al., 2010). In addition to the modulation of astrocytes, modulation of microglia has also been reported in the neuroprotective effects of triptolide in SCI. A study found that in SCI, the
neuroprotection of celastrol on spinal cord injury was achieved by targeting the miR-96/IKKβ/NF-xB pathway and thus inhibiting microglial activation (Huang et al., 2019). Moreover, enhanced autophagy and inhibition of MAPK/ERK1/2 signaling pathway were also found to be involved in the promotion of spinal cord injury repair by triptolide in SCI (Zhu et al., 2020). Furthermore, the neuroprotection of celastrol on SCI was also reported. For example, an in vitro study found that celastrol significantly reduced motor neuron death. As mentioned above, celastrol plays an important role in the induction of Hsp70 in diseases, and there are similar results in the study of SCI, that is, celastrol can play a neuroprotective role by inducing the expression of Hsp70. However, the limited protection of celastrol on the lumbar motor network was found in this study, suggesting that the therapeutic effects of celastrol in SCI are limited (Petrović et al., 2019). In addition, Dai et al. investigated the effects of celastrol on pyroptosis in SCI (Dai et al., 2019). Pyroptosis is a form of cell death that is distinct from necrosis and apoptosis and is associated with immunity and inflammation (Shi et al., 2015). They investigated the effects and mechanisms of celastrol in SCI rats and LPS/adenosine triphosphate (ATP)-induced BV2 cells and found that celastrol attenuated the activation of microglia in the spinal cord, inhibited the expression of pyroptosis-related molecules (NLRP3, caspase-1 and gsdemarin D (GSMD)) and inflammatory cytokines, and increased the levels of anti-inflammatory cytokines. Beside that, their study found that celastrol inhibited the expression of NF-kB, one of the upstream promoters of pyroptosis (Li et al., 2021). These suggest that the protective effects of celastrol against SCI is achieved, at least in part, through the inhibition of pyroptosis. These data suggest that triptolide and celastrol exert therapeutic effects by the following mechanisms: a) attenuating neuroinflammation by targeting miR-96/IKKβ/NF-xB, NF-kB/NLRP3/caspase-1 or MAPK/ERK1/2 pathway, or inducing the expression of Hsp70, b) enhancing autophagy, c) attenuating astrogliosis via inhibiting JAK2/STAT3 pathway.

**4 Effects of triptolide and celastrol on epilepsy**

Epilepsy is a chronic neurological disease with various clinical manifestations, and its typical clinical manifestation is epileptic seizures. As a common brain disorder, epilepsy affects more than 70 million people worldwide, adversely affecting the quality of life of patients (Khan et al., 2020). The etiology of epilepsy is not fully understood. Studies have shown that multiple factors are involved in the pathogenesis of epilepsy, such as genes, infections, structures and immunity (Singh and Trevick, 2016). Abnormal neuronal discharge in the brain is thought to be an important cause of epileptic seizures in epilepsy patients. Such abnormal discharge is associated with loss of neurons, dysfunction of glial cells, and changes in neurotransmitters or neuromodulation. Further, recurrent abnormal discharge of neurons in the brain can lead to neuronal abnormalities and synaptic remodelling, exacerbating epilepsy (He et al., 2021). Currently, drugs such as carbamazepine, phenytoin sodium and valproic acid are commonly used to treat epilepsy. However, their use has some side effects, whereas natural medicines have fewer side effects and are safer. Therefore, research on natural medicines for epilepsy is of clinical importance. Triptolide and celastrol have been found to have potential therapeutic implications in the studies of epilepsy.

**4.1 Triptolide**

Kainic acid is often used to induce epileptic seizures. Pan et al. induced epileptic seizures in rats by intracarotid subcutaneous injection of kainic acid, and in the treated rats, triptolide (15 μg/kg) was administered intraperitoneally daily. The results showed that triptolide had a protective effect on neurons in epileptic rats, and this was associated with increased expression of neuron kvl1.1 in the CA3 region of the hippocampus (Pan et al., 2012). Glial cells play an important role in the pathogenesis of epilepsy, among which microglia are innate immune cells in the central nervous system (CNS), and the expression of MHC II in microglia increases under inflammatory conditions, which can activate CD4+ T cells and promote the inflammatory response (Nakahara et al., 2010). In epileptic rats, this was related to neuronal death (Shaw et al., 1994). An in vitro study used kainic acid-stimulated BV2 microglia to investigate the effect of triptolide on microglia. They found that microglia treated with triptolide for 2 h resulted in inhibition of microglial activation (morphology). Furthermore, treatment with triptolide significantly inhibited MHC II expression in microglia, and further promoter predictions and experimental results showed that this inhibition correlated with the inhibition of AP-1/class II transactivator (Sun et al., 2018).

**4.2 Celastrol**

In addition, several studies have also reported on the therapeutic effects of celastrol on epilepsy. Study has reported that researchers used a multiple-hit rat model to explore the therapeutic effects of celastrol on infantile spasms. Considering the anti-inflammatory effects of celastrol and the important role of inflammation and immunity in epilepsy, their findings found that celastrol could have a therapeutic effect on the disease by inhibiting NF-kB (Schiavone et al., 2021). Moreover, a study found that in a disease model of epilepsy, N-methyl-D-aspartate receptor-mediated activation of nicotinamide adenine dinucleotide phosphate oxidase (NOX) induces rapid release of H$_2$O$_2$, which is associated with epileptic seizures. In hippocampal slices and kainic acid-induced rats, treatment with celastrol inhibited NOX activation and rapid H$_2$O$_2$
release, thereby alleviating epileptic seizures (Malkov et al., 2019). However, a study reported the conflicting results, demonstrating that celastrol increases activation of microglia in hippocampal CA1 and CA3 regions and reduces postkindling seizure thresholds (von Rüden et al., 2019). This makes the effects of celastrol on epilepsy even more complex and requires more experiments to explore.

In conclusion, the research on the therapeutic mechanisms of triptolide and celastrol in epilepsy is still not deep enough, and more in-depth studies are needed to further clarify their mechanisms.

5 Molecular mechanisms of triptolide and celastrol for therapeutic potential

The pathogenesis of neurological diseases is complex and not yet fully elucidated. However, studies have shown that neuroinflammation is involved in the development of neurological diseases and that excessive neuroinflammation exacerbates the severity of the diseases (Ransohoff, 2016). Triptolide and celastrol, two important bioactive components extracted from TWHF, play an important role in attenuating neuroinflammation, thus reducing the severity of neurological diseases. In addition to neuroinflammation, triptolide and celastrol also exert neuroprotective against neurological diseases via neurotrophic effects and other mechanisms. In this process, regulation of neurons, microglia and astrocytes is involved (Figures 2, 3). Considering the important role of neuroinflammation and neurotrophy and the existence of numerous related studies, we will next review the studies about neuroinflammation and neurotrophy first, and finally other related mechanisms of neuroprotection.

5.1 Effects of triptolide and celastrol on neuroinflammation

Inflammation is the body’s response to endogenous and exogenous stimuli and it is important for the body’s self-protection. However, excessive inflammation can lead to dysregulation of inflammation and aggravate the severity of the diseases (Leite et al., 2022). Neuroinflammation has an important role in the pathophysiology of neurological diseases, and triptolide and celastrol have been reported to play a role in attenuating neuroinflammation and thus alleviating neurological diseases. For example, in vivo experiments, triptolide and celastrol inhibited neuroinflammation and attenuated the loss of dopaminergic neurons, thus improving the clinical performance of PD.
animal models (Zhou et al., 2005; Zhang et al., 2021). Further studies revealed that these effects were associated with the inhibition of microglial activation (Li G. et al., 2006). Microglia are innate immune cells of the CNS and are involved in the regulation of neuroinflammation (Young and Denovan-Wright, 2021). Studies have shown that triptolide and celastrol can inhibit the expression of pro-inflammatory molecules (TNF-α, IL-1β, MHC II, COX-2, and prostaglandin E2 (PGE2)) and promote the expression of anti-inflammatory cytokines (IL-4, IL-10 and IL-33) in microglia (Allison et al., 2001; O’Brien et al., 2001; Jiao et al., 2008; Jiang et al., 2018; Sun et al., 2018). Many signaling pathways mentioned have been found to be involved in the process (shown in Figures 2, 3). Among these, the NF-kB signaling pathway, a classical inflammation-related signaling pathway, has been the focus of much research. For example, in animal models of MS, triptolide and celastrol have been reported to reduce neuroinflammation and thereby improve behavioral deficits in model animals by inhibiting NF-kB activity (O’Brien et al., 2001; Wang et al., 2008).

In addition to neurodegenerative diseases, the inhibition of NF-kB activity by triptolide and celastrol has also been reported in studies on cerebral ischemia and spinal cord injury (Bai et al., 2016a; Huang et al., 2019; Liu D. D. et al., 2021). In these studies, the inhibition of NF-kB activity will eventually lead to the decrease in the expression levels of pro-inflammatory molecules, while the related studies about downstream of NF-kB are not clear. A study using SCI rat models and LPS + ATP-induced BV2 cells showed that celastrol inhibits the activity of NF-kB, which in turn inhibits the expression of its downstream, NLRP3 inflammasome-related pathway, exerting anti-inflammatory effects (Dai et al., 2019). This reveals that the inhibition of NF-kB activity by celastrol leads to the decrease in the level of pyroptosis, thereby reducing the severity of the disease. In addition, many studies have reported the effects of triptolide and celastrol on Hsp70. Heat shock proteins are molecular chaperones that can assist in the proper folding of newly synthesized proteins and increase induced by stress (Agashe and Hartl, 2000). Kizelsztein et al. found that triptolide increased the expression level of Hsp70, stabilized the NF-kB/IkBα complex, which in turn inhibited neuroinflammation and exerted neuroprotective effects on the EAE models (Kizelsztein et al., 2009). Furthermore, by using LPS-stimulated PC12 cells, Geng et al. found that triptolide inhibited NF-kB activity and phosphorylation of p38, ERK1/2 and AKT, thus reducing the expression of COX-2 and PGE2 (Geng et al., 2012). This shows that in terms of inhibiting neuroinflammation, in addition to targeting microglia, triptolide can also directly target neurons and reduce the level of inflammation in neurons. Similar results can also be found in related studies of celastrol. For example, it was found that celastrol inhibited NF-kB activity and attenuated inflammation levels in HEK293 cells and LPS-treated H4-APP cells (Paris et al., 2010; Zhao et al., 2014). Moreover, in OGD-treated rat primary cortical neurons, celastrol was reported to directly bind to

FIGURE 3
Mechanisms of action of celastrol in neurological diseases. Similar to triptolide, celastrol has therapeutic potential in neurological diseases, with related mechanisms of action including inhibition of neuroinflammation and promotion of neuroprotection. The NF-kB signaling pathway is also involved in the action of celastrol, and celastrol can also act directly on neurons, thereby exerting neuroprotective effects. Notably, although many studies have identified neurotrophic effects of triptolide, similar results have not been reported in studies related to celastrol.
Hippocampal region of AD murine models (Lu et al., 2019). The above studies demonstrate that triptolide and celastrol can exert neuroprotective effects on neurological diseases by inhibiting neuroinflammation, and their inhibition of neuroinflammation can be achieved by targeting both microglia and neurons.

5.2 Effects of triptolide on neurotrophin

In addition to inhibiting neuroinflammation, neurotrophin is also important to achieve the neuroprotective effects of TWHF extracts on neurological diseases. A previous study reported that triptolide promotes the synthesis and release of NGF from rats primary astrocytes (Xue et al., 2007). This suggests that triptolide can exert neurotrophic effects by affecting astrocytes. However, it did not reveal that whether triptolide can affect astrogliosis and glial scars. Astrocytes are important glial cells within the CNS that can play supportive and nutritional roles for neurons. In the case of injury, astrocyte activation leads to astrogliosis and eventually glial scars formation (Nash et al., 2011). In the early stages of injury, the glial scars separate the injured tissue from the surrounding area and protect the spared tissue (Rolls et al., 2009). However, in the late stage, glial scars prevent axonal regeneration and impair the recovery of function (Yiu and He, 2006). Therefore, it is important to study the effects of triptolide on astrogliosis and glial scar in the injured area. Further study using SCI rat models and LPS-stimulated primary astrocytes revealed that triptolide can inhibit astrogliosis and glial scars formation by affecting the JAK2/STAT3 pathway, which in turn promotes spinal cord repair (Su et al., 2010). Moreover, triptolide and tripchlorolide were also found to increase synaptophysin expression in hippocampal neurons, or BDNF mRNA expression in primary mesencephalic neurons (Li et al., 2003; Nie et al., 2012). Recently, an in vivo study found that triptolide and tripchlorolide increased the expression of neurofilament-1 in the hippocampal region of AD murine models (Lu et al., 2019). These data demonstrate the neurotrophic effects of triptolide in neurological diseases; however, no neurotrophic effect of celastrol has been reported in neurological diseases, and further research is needed.

5.3 Effects of triptolide and celastrol on neuroprotection

Besides that, triptolide and celastrol can also exert neuroprotection against neurological diseases through other mechanisms. Polypeptides misfolding is considered as an important pathogenetic mechanism in neurodegenerative diseases (Sweeney et al., 2017). As mentioned earlier, heat shock proteins act as important molecular chaperones to assist in the proper folding of newly synthesized polypeptides. Therefore, targeting heat shock proteins is one of the effective approaches to treat neurodegenerative diseases. It was found that celastrol increases the expression of Hsp70 in neurons, which in turn exerts neuroprotective effects in neurodegenerative diseases (Cleren et al., 2005; Zhang and Sarge, 2007; Kalmar and Greensmith, 2009; Zhao et al., 2014). Besides that, celastrol was also found to increase the expression of Hsp70 in TBI mouse models and SCI spinal cords models, thus exerting neuroprotective effects (Eroglu et al., 2014; Petrović et al., 2019). In addition to increasing the expression of Hsp70, triptolide and celastrol also exert neuroprotective effects through the following mechanisms: a). decreasing level of oxidative stress. He et al. reported that triptolide inhibited the formation of ROS and the decrease of mitochondrial membrane potential in glutamate-treated PC12 cells (He et al., 2003), b). inhibiting apoptosis. Triptolide inhibits apoptosis by activating the PI3K/AKT/mTOR signaling pathway (Li et al., 2015), c). inducing autophagy. It was reported that triptolide exerts neuroprotection by inducing autophagy in Aβ 25-35-treated differentiated PC12 cells (Xu et al., 2015). Besides that, in MN9D cells, triptolide was found to enhance autophagy in neuronal cells, thus promoting the clearance of a-synuclein (Hu et al., 2017). Moreover, research has shown that celastrol induces autophagy and exerts neuroprotection in rotenone-induced SH-SYSY cells (Deng et al., 2013), d). attenuating glycosylation. Celastrol attenuates glycosylation and exerts neuroprotection by inhibiting HIF-1α/PDK1 pathway (Chen et al., 2022), e). suppressing NOX activation and rapid H2O2 release. Celastrol inhibits NOX activation and prevents fast H2O2 release, which in turn attenuates epileptic seizure (Malkov et al., 2019). Several pathways involved in the neuroprotective effects are shown in Figures 2, 3.

6 Toxicity and derivatives

Although extracts of TWHF can be used to treat a variety of diseases, their toxicity limits clinical application (Li et al., 2014). Among them, triptolide and celastrol have been reported to have hepatotoxicity, nephrotoxicity, cardiotoxicity, reproductive toxicity and hematological toxicity (Table 2) (Bai et al., 2021; Cheng et al., 2021). In addition, poor solubility and bioavailability have also limited the clinical application of triptolide and celastrol, and research on related derivatives (Figure 4) and nanotechnology-based carrier system could improve this situation.

6.1 Toxicity

Triptolide is one of the important TWHF extracts and is widely used in therapeutic studies for a variety of diseases. However, it has some toxicity and may cause serious side
effects, which limits its clinical application. Its toxicity may be related to the epoxide structure covalently binding to and breaking biological macromolecules in the body (Xu et al., 2013). The liver, as an important metabolic organ in the body, has received widespread attention in the toxic damage caused by triptolide. It was found that the administration of triptolide (1 mg/kg) in animal models caused necrosis of hepatocytes with inflammatory cell infiltration, suggesting a possible role...
of inflammation in triptolide-induced liver injury (Wang et al., 2013a). This hypothesis is supported by another study which reported liver damage in animal models following triptolide administration, as well as inhibition of mitochondrial respiratory chain and increased levels of oxidative stress (Fu et al., 2011). In addition, it has been suggested that mitochondrial dysfunction and mitochondrial autophagy may also be involved in triptolide-induced liver injury (Hasnat et al., 2019). In addition to hepatotoxicity, nephrotoxicity of triptolide has also been reported. An in vivo experiment found that the administration of triptolide (1 mg/kg) to rats induced renal damage and increased level of oxidative stress (Yang et al., 2012). Besides that, triptolide-induced kidney damage was also found in a collagen-induced arthritis rat model (Shen et al., 2019).

Moreover, triptolide has been reported to cause reproductive toxicity to both male and female reproductive systems. For example, Ma et al. reported that triptolide can disrupt testicular structure and inhibit spermatogenesis in male mice, which may be associated with downregulation of peroxisome proliferator-activated receptor (PPAR), leading to abnormal energy and lipid metabolism (Ma et al., 2015). As for reproductive toxicity in females, triptolide was found to reduce the expression of estradiol and progesterone in female rats, and the cyclic adenosine monophosphate/protein kinase A pathway may be involved (Zhang et al., 2012a; Zhang et al., 2012b).

Celastrol, one of the main bioactive components extracted from TWHF, has anti-inflammatory, antioxidant, and anti-tumour effects and is therefore used in therapeutic studies for many diseases. However, its toxicity has limited further research in the clinical field. A study reported that celastrol caused liver damage in rats, which may be related to the inhibition of the activity of cytochrome P450s by celastrol (Sun et al., 2014). Hepatotoxicity of celastrol was also found in an in vitro experiment (rat primary hepatocytes) (Jin et al., 2019). Furthermore, celastrol-induced cardiotoxicity has also been reported. Wang et al. reported that severe edema could be found in the pericardial sac after celastrol treatment (1.5 μM) in zebrafish embryos (Wang et al., 2011). Beside that, the cardiotoxicity of celastrol was found in HEK 293 cells, which may be associated with the inhibition of K+ channels (hERG and Kir2.1) activity (Sun et al., 2006). Moreover, Kusy et al. found that celastrol regulated the hematopoietic cell subsets, thus impairing the development of erythrocytes and B cells, and this further caused hematological toxicity in animal models (Kusy et al., 2012).

6.2 Derivatives

Considering the toxicity of triptolide and celastrol, many methods have been used to reduce their toxicity for clinical use. Generally speaking, four methods are usually used including the following: 1) structural modifications, 2) change in processing method, 3) change of the method of administration, and 4) combination of other drugs for co-treatment (Wang et al., 2016). Of these, “structural modification” means investigating derivatives of triptolide and celastrol in order to reduce toxicity, increase efficacy and facilitate clinical application. Structure-activity relationships are important in structural modifications. According to the structure-activity relationship, the derivatives of triptolide obtained after structural modification mainly include omtriptolide (PG490-88) (Kitzen et al., 2009), minnelide (Rivard et al., 2014) and (5R)-5-Hydroxytriptolide (LLDT-8) (Guo et al., 2019). In addition, derivatives of celastrol have also been reported. Celastrol is a triterpenoid quinone methide, and the relevant structural modifications are mainly the C-29 carboxyl group and the A/B ring modification (Bai et al., 2021). Studies have reported that these derivatives can reduce toxicity, increase bioavailability and be more beneficial for clinical applications in a variety of diseases (Zheng et al., 2013; Li and Hao, 2019).

6.3 Nanotechnology-based carrier system

With the advancement of nanoscience, nano-sized carriers are being used for drug loading and the nanotechnology-based carrier system can improve the effectiveness of triptolide and celastrol and reduce their toxicity. Studies have demonstrated that triptolide can be encapsulated to form triptolide-loaded nanomaterials, thus decreasing excessive accumulation of triptolide in normal tissues and reducing its toxicity. A study used triptolide-loaded liposomes, which linked anti-carbonic anhydrase IX antibody (an enzyme overexpressed on the surface of lung cancer cells) on the surface, to improve the treatment effects of triptolide on lung cancer cells (Lin et al., 2017). In addition, inflammation-targeted amphiphilic galactosyl dextran-retinal nanoparticles were used to encapsulate triptolide and the all-trans retinal, which is not only conducive to the drug delivery, but also can exert the synergistic effect of the drugs, thereby significantly enhancing the anti-inflammatory effect (Li et al., 2020). Similar to triptolide, celastrol can also be loaded by nanomaterials, which in turn reduces toxicity, increases bioavailability and enhances therapeutic efficacy. Studies have shown that celastrol can be loaded by various types of nanomaterials, such as liposomes, lipid nanoparticles, and exosomes, and the nanomaterials loaded with celastrol are used to treat various diseases (Guo et al., 2021). However, studies on nanotechnology-based carrier system of triptolide and celastrol are mainly about cancer therapy, and there are fewer studies related to neurological diseases (Liaw et al., 2021; Geng et al., 2022). Therefore, more studies are needed to confirm the efficacy of triptolide-loaded or celastrol-loaded nanomaterials for neurological diseases.
7 Conclusion

Neurological diseases can affect the brain and spinal cord and cause the corresponding clinical symptoms, which place a greater burden on the patient and society. Therefore, the treatment of neurological diseases is urgent and important. The pathogenesis of neurological diseases is complex and most of them are not due to a single factor; therefore, treatment based on a single-factor etiology is ineffective. Traditional Chinese medicine has a long history of medicinal use in China, with a wide range of targets, and is used for the treatment of many diseases. With the development of modern technology, the research of phytochemical research has gained tremendous progress. Extracts of TWHF (traditional Chinese medicine), triptolide and celastrol, have attracted great interest from researchers because of their structural characteristics and multi-target effects, and have been used in preclinical studies for a variety of neurological diseases involving neurodegenerative diseases, brain and spinal cord injuries, and epilepsy.

Although triptolide and celastrol have excellent potential therapeutic effects, poor water solubility, low oral bioavailability, imprecision of mechanism of action and potential toxicity limit their clinical application. Therefore, many methods have been used to address these problem, such as structural modifications, change in processing method, change of the method of administration, combination of other drugs for co-treatment, and the use of nanotechnology-based carrier system. In addition, to date, there have been no clinical trials to validate the therapeutic effects of triptolide and celastrol in neurological diseases to translate preclinical studies into clinical studies. Considering the potent therapeutic effects of triptolide and celastrol in neurological diseases, further studies on the pathogenesis of neurological diseases, and the mechanism of action, structure-activity relationships and pharmacokinetics of triptolide and celastrol would help to enhance their clinical application. Moreover, the development of nanotechnology can also facilitate the full utilization of these compounds.

Author contributions

JF was responsible to conceive, design, and revise this review. YC searched and collected the related references and wrote the original manuscript. XJ completed the figures and tables.

Funding

This review was supported by the Outstanding Scientific Fund of Shengjing Hospital (to JF), Key Research and Development Program of Liaoning Province (No. 2020JH2/10300047 to JF), and National Natural Science Foundation of China (No. 81771271 to JF).

Acknowledgments

We gratefully thank members of Feng’s lab for their intellectual input.

Conflict of interest

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Publisher’s note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

References

Abakumova, T. O., Kuz’kina, A. A., Zharova, M. V., Pozdeeva, D. A., Gubskii, I. L., Shepeleva, I. I., et al. (2015). Erratum to: Cuprizone model as a tool for preclinical studies of the efficacy of multiple sclerosis diagnosis and therapy. Bull. Exp. Biol. Med. 159 (3), 341. doi:10.1007/s10517-015-2976-8

Abdin, A. A., and Hasby, E. A. (2014). Modulatory effect of celastrol on Th1/Th2 cytokines profile, TLR2 and CD3+ T-lymphocyte expression in a relapsing-remitting model of multiple sclerosis in rats. Eur. J. Pharmacol. 742, 102–112. doi:10.1016/j.ejphar.2014.09.001

Agashe, V. R., and Harlf, F. U. (2000). Roles of molecular chaperones in cytoplasmic protein folding. Semin. Cell Dev. Biol. 11 (1), 15–25. doi:10.1006/scdb.1999.0347

Allison, A. C., Cacabelos, R., Lombardi, V. R., Alvarez, X. A., and Vigo, C. (2001). Celastrol, a potent antioxidant and anti-inflammatory drug, as a possible treatment for Alzheimer’s disease. Prog. Neuropsychopharmacol. Biol. Psychiatry 25 (7), 1341–1357. doi:10.1016/s0278-5846(01)00192-0

Andrieu, S., Coley, N., Lovestone, S., Aisen, P. S., and Vellas, B. (2015). Prevention of sporadic alzheimer’s disease: Lessons learned from clinical trials and future directions. Lancet. Neurol. 14 (9), 926–944. doi:10.1016/s1474-4422(15)00153-2

Arena, G., Sharma, K., Agyeh, G., Krieger, R., Grunewald, A., and Fitzgerald, J. C. (2012). Neurodegeneration and neuroinflammation in Parkinson’s disease: A self-sustained loop. Curr. Neural. Neurosci. Rep. 12 (8), 427–440. doi:10.1007/s11910-012-01207-5

Bai, S., Hu, Z., Yang, Y., Yin, Y., Li, W., Wu, L., et al. (2016a). Anti-inflammatory and neuroprotective effects of triptolide via the NF-κB signaling pathway in a rat MCAO model. Anat. Res. 299 (2), 256–266. doi:10.1002/ar.23295

Bai, S., Sun, Y., Wu, L., Wu, Z., and Fang, M. (2016b). Tripotolide ameliorates inflammation and apoptosis induced by focal cerebral ischemia/reperfusion in rats. Zhongguo Da Xue Xue Bao Yi Xue Ban. 45 (5), 493–500. doi:10.3785/j.issn.1008-9292.2016.09.07
Bai, X., Fu, R. J., Zhang, S., Yue, S. J., Chen, Y. Y., Xu, D. Q., et al. (2021). Potential medicinal value of celastrol and its synthesized analogues for central nervous system diseases. Biomed. Pharma. Therapeutics. 139, 111551. doi:10.1016/j.biopha.2021.111551
Baloh, P., Margenthaler, E., Reed, J., Crawford, F., and Mullan, M. (2011). Depletion of CXXC2 inhibits γ-secretase activity and amyloid-β production in a murine model of Alzheimer’s disease. Cytokine 53 (2), 163–169. doi:10.1016/j.cyt.2010.10.008
Benjamin, E. J., Virani, S. S., Callaway, C. W., Chamberlain, A. M., Chang, A. R., Cheng, S., et al. (2018). Heart disease and stroke statistics-2018 update: A report from the American heart association. Circulation 137 (12), e67–e492. doi:10.1161/circ.0000000000000558
Borsosoki, D. (2012). Neurological diseases and pain. Brain 135, 320–344. doi:10.1093/brainaw271
Brefait, C., Gras, M., Liot, D., May, V., Vaudry, D., and Wurtz, O. (2015). Delayed putatory adenylate cyclase-activating polypeptide delivery after brain stroke improves functional recovery by inducing m2 microglia/macrophage polarization. Stroke 46 (2), 520–528. doi:10.1161/strokeaha.114.006864
Brinker, A. M., Ma, J., Lipsky, P. E., and Raskin, I. (2007). Medicinal chemistry and pharmacology of genus Tripterygium (Celastraceae). Phytochemistry 68 (6), 732–766. doi:10.1016/j.phytochem.2006.11.029
Burrmistrtova, O., Olas-Arjona, A., Lapresa, R., Jimenez-Blasco, D., Eremerova, T., Shishov, D., et al. (2019). Targeting PFKFB3 alleviates cerebral ischemia-reperfusion injury in mice. Oxid. Med. Cell. Longev. 2019, 6527638. doi:10.1155/2019/6527638
Cao, F., Wang, Y., Peng, R., Zhang, X., Zhang, D., and Xu, L. (2018). Effects of celastrol on Tau hyperphosphorylation and expression of HSF-1 and HSP70 in SH-SYSY neuroblastoma cells induced by amyloid-β peptides. Biotechnol. Appl. Biochem. 65 (3), 390–396. doi:10.1021/ab6b1633
Chen, M., Liu, M., Luo, Y., Cao, J., Zeng, F., Yang, L., et al. (2022). Celastrol protects against cerebral ischemia/reperfusion injury in mice by inhibiting glycolysis through targeting HIF-1α/PDK1 Axis. Oxid. Med. Cell. Longev. 2022, 7420507. doi:10.1155/2022/7420507
Cheng, S., LeBlanc, K. J., and Li, L. (2014). Triptolide preserves cognitive function and reduces neuroatropathy in a mouse model of Alzheimer’s disease. PLoS One 9 (10), e80685. doi:10.1371/journal.pone.0080685
Cheng, X. X., Li, F. Q., Huang, M., Wang, X. M., and Han, J. S. (2002). Protective effect of triphlorocond on dopaminergic neurons in partially lesioned rat model of Parkinson’s disease. Yao Xue Xue Bao 37 (5), 339–342.
Cheng, Y., Zhao, Y., and Zheng, Y. (2021). Therapeutic potential of triptolide in autoimmune diseases and strategies to reduce its toxicity. Chin. Med. 16 (1), 114. doi:10.1007/s12021-020-00525-x
Choi, B. S., Kim, H., Lee, H. J., Sapkota, K., Park, S. E., Kim, S., et al. (2014). Celastrol from ‘Thunder God Vine’ protects SH-SYSY cells through the preservation of mitochondrial function and inhibition of p38 MAPK in a rotenone model of Parkinson’s disease. Neurochem. Res. 39 (1), 84–96. doi:10.1007/s11064-013-1193-y
Chow, A. M., Tang, D. W., Hanif, A., and Brown, I. R. (2013). Induction of heat shock proteins in cerebral cortical cultures from rotenone-induced injury through induction of autophagy. Neurochem. Res. 11.029. doi:10.1007/imm.2013.04.005
Di Mitri, D., Sambucci, M., Loiarro, M., Deardi, M., Velpe, E., Cencioni, M. T., et al. (2015). The p53 mitogen-activated protein kinase cascade modulates T helper type 17 differentiation and functionality in multiple sclerosis. Immunology 146 (2), 251–263. doi:10.1111/immm.12497
Dobson, R., and Giovannoni, G. (2019). Multiple sclerosis - a review. Eur. J. Neurol. 26 (1), 27–40. doi:10.1111/ene.13819
Du, X., Guo, F., Chen, S., Botchway, B. O. A., Amin, N., Hu, Z., et al. (2020). Combining pretreatment of colony-stimulating factor 1 receptor inhibitor and triptolide upregulates BDNF-akt and autophagic pathways to improve cerebral ischemia. Mediat. Inflamm. 2020, 8796103. doi:10.1155/2020/8796103
Erogul, B., Kimbrell, D. E., Pang, J., Choi, J., Moskopidis, D., Yanasak, N., et al. (2014). Therapeutic inducers of the HSFP7/HSP110 protect mice against traumatic brain injury. J. Neurochem. 130 (5), 626–641. doi:10.1111/jnc.12781
Faust, K., Gehre, S., Yang, Y., Yang, L., Beal, M. F., and Lu, B. (2009). Neuroprotective effects of compounds with antioxidant and anti-inflammatory properties in a Drosophila model of Parkinson’s disease. BMC Neurol. 10, 109. doi:10.1186/1471-2202-10-109
Fehlings, M. G., and Tator, C. H. (1995). The relationships among the severity of spinal cord injury, residual neurological function, axon counts, and counts of retrogradely labeled neurons after experimental spinal cord injury. Exp. Neurol. 132 (2), 220–228. doi:10.1006/exnr.1995.1007
Feng, Y., Zhang, C., Zhang, Y., Xing, C., Cai, W., Li, R., et al. (2019). Triptolide inhibits preformed fibril-induced microglial activation by targeting the MicroRNA155-5p/SHIP1 pathway. Oxid. Med. Cell. Longev. 2019, 6527638. doi:10.1155/2019/6527638
Fu, Q., Huang, X., Shu, B., Xue, M., Zhang, P., Wang, T., et al. (2011). Inhibition of mitochondrial respiratory chain is involved in triptolide-induced liver injury. Fitoterapia 82 (1), 1244–1248. doi:10.1016/j.fitote.2011.08.019
Fu, Y. F., Zhu, Y. N., Ni, J., Zheng, X. G., Tang, W., Zhou, R., et al. (2006). (5R)-5-hydroxytriptolide (LLDT-8), a novel triptolide derivative, prevents experimental autoimmune encephalomyelitis via inhibiting T cell activation. J. Neuroimmunol. 175 (1–2), 142–151. doi:10.1016/j.jneuroim.2006.03.011
Ganguly, U., Singh, S., Chakrabarti, S., Saini, A. K., and Saini, R. V. (2022). Immunotherapeutic interventions in Parkinson’s disease: Focus on α-Synuclein. Adv. Protein Chem. Struct. Biol. 129, 381–433. doi:10.1016/bs.apscb.2021.11.010
Gao, J. P., Sun, S., Li, W. W., Chen, Y. P., and Cai, D. F. (2008). Triptolide protects against 1-methyl-4-phenyl-pyridinium-induced dopaminergic neurotoxicity in rats: Implication for immunosuppressive therapy in Parkinson’s disease. Neurosci. Bull. 24 (3), 133–142. doi:10.1007/s12264-008-1225-9
Gao, J., Zhang, Y., Liu, X., Wu, X., Huang, L., and Gao, W. (2021). Triptolide: Pharmaceutico-spectrum, biosynthesis, chemical synthesis and derivatives. Theranostics 11 (15), 7199–7221. doi:10.7150/thno.57745
García-Mesa, Y., García-Puertas, J., Cuendias, P., Cobo, R., Martín-Cruces, J., Feito, J., et al. (2022). Synaptophysin is a selective marker for axons in human cutaneous end organ complexes. Annu. Anat. 243, 151955. doi:10.1016/j.anaat.2022.151955
Gehrmann, J., Gold, R., Linington, C., Lannes-Vieira, J., Wekerle, H., and Kreutzberg, G. W. (1993). Microglial involvement in experimental autoimmune inflammation of the central and peripheral nervous system. Glia 7 (1), 50–59. doi:10.1002/glia.440070110
Geng, Y., Fang, M., Wang, J., Yu, H., Hu, Z., Yew, D. T., et al. (2012). Triptolide down-regulates COX-2 expression and PGE2 release by suppressing the activity of...
NF-kB and MAP kinases in lipopolysaccharide-treated PC12 cells. *Phytomer. Res.* 26 (3), 337–343. doi:10.1016/j.pr.2003.05.002

Geng, Y., Xiang, J., Shao, S., Tang, J., and Shen, Y. (2022). Mitochondria-targeted polymer-casted conjugate with enhanced anticancer efficacy. *J. Control. Release* 342, 122–133. doi:10.1016/j.jconrel.2022.01.002

Gu, M., Zhou, H. F., Xue, B., Niu, D. B., He, Q. H., and Wang, X. M. (2004). Effect of Chinese herb Tripterygium wilfordii Hook F monomer triptolide on apoptosis of PC12 cells induced by Abeta-42. *Sheng Li Xue Bao* 56 (1), 73–78.

Guo, L., Zhang, Y., and Al-Jamal, K. T. (2021). Recent progress in nanotechnology-based drug carriers for celastrol delivery. *Biomater. Sci.* 9 (19), 6355–6380. doi:10.1039/d0bm00639h

Guo, S., Liu, J., Jiang, T., Lee, D., Wang, R., Zhou, X., et al. (2019). (5R)-5-Hydroxytriptolide (LLDT-8) induces substantial endogenous mediated immune response network changes in fibroblast-like synoviocytes from rheumatoid arthritis patients. *Sci. Rep.* 9 (1), 11155. doi:10.1038/s41598-019-47411-1

Hao, M., Li, X., Feng, J., and Pan, N. (2015). Triptolide protects against ischemic stroke in rats. *Inflammation* 38 (4), 1617–1623. doi:10.1007/s10753-015-0137-x

Hasnat, M., Yuan, Z., Naveed, M., Khan, A., Raza, F., Xu, D., et al. (2019). Triptolide ameliorates the clinical signs of experimental autoimmune encephalomyelitis (EAE) by induction of HS7P and stabilization of NF-kappaB/IkappaBalpha transcriptional complex. *J. Neuroinflam.* 21 (17), 1–28. doi:10.1186/s12974-019-1001-7

Kiaeri, M., Kipiani, K., Petri, S., Chen, J., Calingasan, N. Y., and Beal, M. F. (2005). Celastrol blocks neuronal cell death and extends life in transgenic mouse model of amyotrophic lateral sclerosis. *Neurogene. Dis.* 2 (5), 246–254. doi:10.1055/s-2005-850536

Kurowska, Z., Englund, E., Widner, H., Lindvall, O., Li, Y., and Brandt, P. (2012). Development of B cells and erythrocytes is specifically impaired by the drug celastrol in mice. *PLoS One* 7 (4), e33573. doi:10.1371/journal.pone.0033573

Lange, B. M., Fischedick, J. T., Lange, M. F., Srividya, N., Sames, C., and Poizner, B. (2017). Integrative approaches for the identification and localization of specialized metabolites in Tripterygium roots. *Plant Physiol.* 173 (1), 456–469. doi:10.1095/bi.2016.114765

Lee, H. F., Lee, T. S., and Kou, Y. R. (2012). Modulation by ouabain. *Front. Physiol.* 3, 281. doi:10.3389/fphys.2012.00281

Li, B., Bai, J., Yang, G., Li, Z., Wang, L., and Chen, Y. (2006). A novel method to evaluate silence of microRNA in vitro. *Biotechnol. Lett.* 28 (10), 1423–1427. doi:10.1007/s10529-006-9185-7

Li, F. Q., Lu, X. Z., Liang, X. B., Zhou, H. F., Xue, B., Liu, X. Y., et al. (2004). Triptolide up-regulates metabot ropic glutamate receptor 5 to inhibit proinflammatory cytokine production in human monocytes. *Life Sci.* 74 (4-5), 513–523. doi:10.1016/j.lfs.2003.09.040

Lin, C., Wu, Z., Wang, L., Kanai, Y., and He, X. (2019). CYP450s-Activity relations and control interac...
Li, J., and Hao, J. (2019). Treatment of neurodegenerative diseases with bioactive components of Tripterygium wilfordii. Am. J. Chin. Med. 47 (04), 769–785. doi:10.1142/s012904941950040x

Li, J. M., Zhang, Y., Tang, L., Chen, Y. H., Guo, Q., Bao, M. H., et al. (2016). Effects of triptolide on hippocampal microglial cells and astrocytes in the APP/PS1 double transgenic mouse model of Alzheimer’s disease. Neural Regen. Res. 11 (9), 1492–1498. doi:10.5117/1673-5574.191224

Li, P., Yang, X., Yang, Y., He, H., Chou, C. K., Chen, F., et al. (2020). Synergistic efficacy of all-trans-retinal and triptolide encapsulated in an inflammation-targeted nanoparticle on collagen-induced arthritis in mice. J. Control. Release 319, 87–103. doi:10.1016/j.jconrel.2019.12.025

Li, W., Yang, H., Zu, L., Ling, S., and Fang, M. (2015). Neuroprotective effects of DAHP and Triptolide in focal cerebral ischemia via apoptosis inhibition and PI3K/Akt/mTOR pathway activation. Front. Neurosci. 9, 48. doi:10.3389/fnins.2015.00048

Li, X. J., Jiang, Z. Z., and Zhang, L. Y. (2014). Triptolide: Progress on research in pharmacodynamics and toxicology. J. Ethnopharmacol. 155 (1), 67–79. doi:10.1016/j.jep.2014.06.006

Li, Y., He, D., Zhang, X., Liu, Z., Xiong, D., et al. (2012). Protective effect of celestrol in rat cerebral ischemia model: Down-regulating p-JNK, p-c-Jun and NF-kB. Brain Res. 1464, 8–13. doi:10.1016/j.brainres.2012.04.054

Li, Y. H., Liu, S. B., Zhang, H. Y., Zhou, F. H., Liu, Y. X., Lu, Q., et al. (2017). Antioxidant effects of celestrol against hydrogen peroxide-induced oxidative stress in the cell model of amyotrophic lateral sclerosis. Sheng Li Xue Bao 69 (6), 751–758.

Li, Y., Xiao, Y., Yin, S., Fan, W., Hu, J., Kou, L., et al. (2021). Targeting microglial alpha-synuclein/TLRs/NF-kappaB/NLRP3 inflammasome Axis in Parkinson’s disease. Front. Immunol. 12, 719807. doi:10.3389/fimmu.2021.719807

Liao, W. T., Xiao, Y. X., Zhu, Y., and Zhou, S. P. (2018). The effect of celestrol on learning and memory in diabetic rats after sevoflurane inhalation. Arch. Med. Sci. 14 (2), 370–380. doi:10.5114/ams.2016.63740

Liaw, K., Sharma, R., Sharma, A., Salazar, S., Appiani La Rosa, S., and Kanner, R. M. (2021). Systemic dendrimer delivery of triptolide to tumor-associated macrophages improves anti-tumor efficacy and reduces systemic toxicity in glioblastoma. J. Control. Release 329, 434–444. doi:10.1016/j.jconrel.2020.12.010

Lin, C., Wong, B. C. K., Chen, H., Bian, Z., Zhang, G., Zhang, X., et al. (2017). Neuroprotective effects of celastrol on the synaptophysin expression of hippocampal neurons in the AD model. Sci. Rep. 8, 1186/s12974-017-01203-x

Ma, B., Xu, H., Cui, L., Liu, Z., Zhang, X., Dong, L., et al. (2012). Protective effect of celastrol on the infiltration of T lymphocytes and expression of icam-1 in the hippocampus of patients with hippocampal sclerosis. Acta histochem. cytochem. 43 (6), 157–162. doi:10.1267/ahc.10022

Meng, H., Jin, W., Yu, L., Xu, S., Wan, H., and He, Y. (2021). Protective effects of polysaccharides on cerebral ischemia: A mini-review of the mechanisms. Int. J. Biol. Macromol. 169, 463–472. doi:10.1016/j.ijbiomac.2020.12.124

Monteine, T. J., Phelps, C. H., Beach, T. G., Bigio, E. H., Cairns, N. J., Dickson, D. W., et al. (2012). National institute on aging-alzheimer’s association guidelines for the neuropathologic assessment of alzheimer’s disease: A practical approach. Acta Neuropathol. 123 (1), 1–11. doi:10.1007/s00401-011-0910-3

Mousadda, A., Demchuk, A. M., and Hill, M. D. (2018). Thrombolytic therapies for ischemic stroke: Triumphs and future challenges. Neuropharmacology 134, 272–279. doi:10.1016/j.neuropharm.2017.11.010

Nakahara, H., Konishi, Y., Beach, T. G., Yamada, N., Makino, S., and Toyama, Y. (2010). Infiltration of T lymphocytes and expression of icam-1 in the hippocampus of patients with hippocampal sclerosis. Acta histochem. cytochem. 43 (6), 157–162. doi:10.1267/ahc.10022

Nie, J., Zhou, M., Liu, C., Hu, X., Wan, B., Yang, B., et al. (2012). Effects of triptolide on the synaptophysin expression of hippocampal neurons in the AD cellular model. Int. Immunopharmacol. 13 (2), 175–180. doi:10.1016/j.intimp.2012.03.021

Nie, J., Zhou, M., Liu, C., Hu, X., Wan, B., Yang, B., et al. (2012). Effects of triptolide on the synaptophysin expression of hippocampal neurons in the AD cellular model. Int. Immunopharmacol. 13 (2), 175–180. doi:10.1016/j.intimp.2012.03.021

O'Brien, N. C., Charlton, B., Cowden, W. B., and Willenborg, D. O. (2001). Inhibition of nitric oxide synthase initiates relapsing remitting experimental autoimmune encephalomyelitis in rats, yet nitric oxide appears to be essential for clinical expression of disease. J. Immunol. 167 (10), 5904–5912. doi:10.4049/jimmunol.167.10.5904

Pan, W., and Xu, Z. (2020). Triptolide mediates Wnt/beta-catenin signalling pathway to reduce cerebral ischemia-reperfusion injury in rats. Folia Neuropathol. 58 (4), 324–333. doi:10.5114/fn.2020.102435

Pan, X., Zou, S. F., Zeng, C. X., Cui, J. H., Hu, B., and Li, Y. W. (2012). Effects of triptolide on kV1.1 expression of voltage-gated potassium channels in epileptic rats. Int. J. Neurol. Neurosurg. 39 (2), 108–113. doi:10.7666/dy158041

Paris, D., Ganey, N. J., Laporte, V., Patel, N. S., Beaulieu-Abdelhadi, D., Bachmeier, C., et al. (2010). Reduction of beta-amyloid pathology by celastrol in a transgenic mouse model of Alzheimer’s disease. J. Neuroinflammation 7, 17. doi:10.1186/1744-8013-7-17

Perry, V. H., Nicoll, J. A., and Holmes, C. (2010). Microglia in neurodegenerative disease. Nat. Rev. Neurosci. 11 (4), 193–201. doi:10.1038/nrn2870.10.17

Petrović, A., Kaur, J., Tomljanović, I., Nistri, A., and Mladinic, M. (2019). Pharmacological induction of Heat Shock Protein 70 by celestrol protects motor neurones from excitotoxicity in rat spinal cord in vitro. Eur. J. Neurosci. 49 (2), 215–231. doi:10.1111/ejn.14218

Postuma, R. B., Berg, D., Stern, M., Poewe, W., Olanow, C. W., Oertel, W., et al. (2015). MDS clinical diagnostic criteria for Parkinson’s disease. Mov. Disord. 30 (12), 1591–1601. doi:10.1002/mds.26424

Rai, S. N., Singh, B. K., Rathore, A. S., Zabra, W., Keswani, C., Birla, H., et al. (2019). Quality control in huntington’s disease: A therapeutic target. Neurotox. Res. 36 (3), 612–626. doi:10.1007/s12640-019-00087-x

Rosenthal, R. M. (2016). How neuroinflammation contributes to neurodegeneration. Science 353 (6301), 777–783. doi:10.1126/science.aag2590

Rivard, C., Geller, M., Schennert, E., Saluja, M., Vogel, R. I., Saluja, A., et al. (2014). Inhibition of epithelial ovarian cancer by Minoclone, a water-soluble prodrug. Gynecol. Oncol. 135 (2), 318–324. doi:10.1016/j.ygyno.2014.08.031
Villegas-Llerena, C., Phillips, A., Garcia-Reithboeck, P., Hardy, J., and Pocock, J. M. (2016). Microglial genes regulating neuroinflammation in the progression of Alzheimer’s disease. Curr. Opin. Neurobiol. 36, 74–81. doi:10.1016/j.conb.2015.10.004

Vojnovic, D., Kalaosa, M., Trompet, S., Fischer, K., Shipley, M. J., Li, S., et al. (2020). Association of circulating metabolites in plasma or serum and risk of stroke: Meta-analysis from seven prospective cohorts. Neurology 96 (8), e110–e123. doi:10.1212/WNL.0000000000011236

von Rüden, E. I., Wolf, F., Guattieri, F., Keck, M., Hunt, C. R., Pandita, T. K., et al. (2019). Genetic and pharmacological targeting of heat shock protein 70 in the mouse amygdala-kindling model. ACS Chem. Neurosci. 10 (3), 1434–1444. doi:10.1021/acschemneuro.8b00475

Wan, B., Hu, X., Nie, J., Zhou, M., Yang, B., Li, Y., et al. (2014). Effects of triptolide on degeneration of dentritic spines induced by Aβ40 injection in rat hippocampus. Neurol. Sci. 35 (1), 35–40. doi:10.1007/s10072-013-1463-0

Wan, Y. S., You, Y., Ding, Q. Y., Xu, Y. X., Chen, H., Wang, R. R., et al. (2022). Triptolide protects against white matter injury induced by chronic cerebral hypoperfusion in mice. Acta Pharmacol. Sin. 43 (1), 15–25. doi:10.1038/s41401-021-00637-0

Wang, C., Han, H., Li, and Zhang, C. (2021). Celastrol attenuates ischemia/reperfusion-mediated memory dysfunction by downregulating AK005401/MAP3K12. PLoS One 16 (2), e0243715. doi:10.1371/journal.pone.0243715

Wang, J., Gines, S., MacDonald, M. E., and Gusella, J. F. (2005). Reversal of a full-length mutant huntingtin neuronal cell phenotype by chemical inhibitors of polyglutamine-mediated aggregation. BMC Neurol. 6, 1. doi:10.1186/1471-2202-6-1

Wang, J., Gu, B. J., Masters, C. L., and Wang, Y. F. (2017). A systemic view of Alzheimer disease - insights from amyloid-β metabolism beyond the brain. Nat. Rev. Neurosci. 18 (11), 703. doi:10.1038/nrneurol.2017.147

Wang, J., Jiang, Z., Ji, J., Wang, W., Wang, T., Zhang, Y., et al. (2013a). Gene expression profiling and pathway analysis of hepatotoxicity induced by triptolide in Wistar rats. Food Chem. Toxicol. 58, 495–505. doi:10.1016/j.fct.2013.04.039

Wang, J., Shi, Z. Q., Xu, X., Xin, G. Z., Chen, J., Qi, L. W., et al. (2013b). Triptolide inhibits amyloid-β production and protects neural cells by inhibiting CXCR2 activity. J. Alzheimers Dis. 33 (1), 217–229. doi:10.3233/JAD-120841

Wang, Q., Meng, J., Dong, A., Yu, J. Z., Zhang, G. X., and Ma, C. G. (2016). The pharmacological effects and mechanism of Tripterygium wolffiodi Hook F in central nervous system autoimmune. J. Altern. Complement. Med. 22 (7), 496–502. doi:10.1089/acm.2016.0004

Wang, Q., Xiao, B., Cui, S., Song, H., Qian, Y., Dong, L., et al. (2014). Triptolide treatment reduces Alzheimer’s disease (AD)-like pathology through inhibition of BACE1 in a transgenic mouse model of AD. Dis. Model. Mech. 7 (12), 1385–1395. doi:10.1242/dmm.018218

Wang, S., Liu, K., Wang, W., He, Q., and Chen, X. (2011). Toxic effects of celastrol on embryonic development of zebrafish (Danio rerio). Drug Chem. Toxicol. 34 (1), 61–65. doi:10.3109/0148004510494664

Wang, Y., Cao, L., Xu, L. M., Cao, F. F., Feng, B., Zhang, X., et al. (2015). Celastrol ameliorates EAE induction by suppressing pathogenic T cell responses in the peripheral and central nervous systems. J. Neuroimmune Pharmacol. 10 (3), 506–516. doi:10.1007/s11481-015-9598-9

Wang, Y., Mei, Y., Feng, D., and Xu, L. (2008). Triptolide modulates T-cell inflammatory responses and ameliorates experimental autoimmune encephalomyelitis. J. Neurosci. 28 (6), 12441–12449. doi:10.1523/JNEUROSCI.2683-12.2013

Wei, D. M., Huang, G. Z., Zhang, Y. G., and Rao, G. X. (2004). Influence of triptolide on neuronal apoptosis in rat with cerebral injury after focal ischemia reperfusion. Zhongguo Zhong Yao Za Zhi 29 (11), 1089–1091, 1116.

Xu, Y. Y., Liao, B. Y., Xiao, D., Wu, W. C., Xiao, Y., Alexander, T., et al. (2022). Encapsulation of hryosatin-1 by targeted exosomes enhances remyelination and neuroprotection effects in the cuprizone-induced demyelinating animal model of multiple sclerosis. Biomater. Sci. 10 (3), 714–727. doi:10.1039/d1bm01142a

Xiao, Y., Wang, W., Wang, S., Li, J., Xu, X., Wang, M., et al. (2021). Celastrol attenuates learning and memory deficits in an Alzheimer’s disease rat model. Biomol. Res. Int. 2021, 5574207. doi:10.1155/2021/5574207

Xu, L., Qiu, Y., Xu, H., Ao, W., Lam, W., and Yang, X. (2013). Acute and subacute toxicity studies on triptolide and triptolide-loaded polymeric micelles following intravenous administration in rodents. Food Chem. Toxicol. 57, 371–379. doi:10.1016/j.fct.2013.05.044

Xu, P., Li, Z., Wang, H., Zhang, X., and Yang, Z. (2015). Triptolide inhibited cytotoxicity of differentiated PC12 cells induced by amyloid-beta via the amyphagous pathway. PLoS One 10, e0142719. doi:10.1371/journal.pone.0142719
Xu, P., Wang, H., Li, Z., and Yang, Z. (2016). Triptolide attenuated injury via inhibiting oxidative stress in Amyloid-Beta25-35-treated differentiated PC12 cells. Life Sci. 145, 19–26. doi:10.1016/j.lfs.2015.12.018

Xue, B., Jiao, J., Zhang, L., Li, K. R., Gong, Y. T., Xie, J. X., et al. (2007). Triptolide upregulates NGF synthesis in rat astrocyte cultures. Neurochem. Res. 32 (7), 1113–1119. doi:10.1007/s11064-006-9253-1

Yang, C., Li, S., Huang, X., Chen, X., Shan, H., Chen, X., et al. (2022a). Silk fibroin hydrogels could be therapeutic biomaterials for neurological diseases. Oxid. Med. Cell. Longev. 2022, 2076680. doi:10.1155/2022/2076680

Yang, C., Su, C., Iyaswamy, A., Krishnamoorthi, S. K., Zhu, Z., Yang, S., et al. (2022b). Celastrol enhances transcription factor EB (TFEB)-mediated autophagy and mitigates Tau pathology: Implications for Alzheimer’s disease therapy. Acta Pharm. Sin. B 11 (3), 824. doi:10.1016/j.apsb.2021.11.003

Yang, F., Ren, L., Zhao, L., Ananda, S., and Liu, L. (2012). Involvement of oxidative stress in the mechanism of triptolide-induced acute nephrotoxicity in rats. Exp. Toxicol. Pathol. 64 (7-8), 905–911. doi:10.1016/j.etp.2011.03.013

Yang, H., Liu, C., Jiang, J., Wang, Y., and Zhang, X. (2017). Celastrol attenuates multiple sclerosis and optic neuritis in an experimental autoimmune encephalomyelitis model. Front. Pharmacol. 8, 44. doi:10.3389/fphar.2017.00044

Yang, Y., Gao, K., Hu, Z., Li, W., Davies, H., Ling, S., et al. (2015). Autophagy upregulation and apoptosis downregulation in DAHP and triptolide treated cerebral ischemia. Mediat. Inflamm. 2015, 120198. doi:10.1155/2015/120198

Yiu, G., and He, Z. (2006). Glial inhibition of CNS axon regeneration. Nat. Rev. Neurosci. 7 (8), 617–627. doi:10.1038/nrn1956

Yoshizaki, K., Adachi, K., Kataoka, S., Watanabe, A., Tabira, T., Takahashi, K., et al. (2008). Chronic cerebral hyperperfusion induced by right unilateral common carotid artery occlusion causes delayed white matter lesions and cognitive impairment in adult mice. Exp. Neurol. 210 (2), 585–591. doi:10.1016/j.expneurol.2007.12.005

Young, A. P., and Denovan-Wright, E. M. (2021). The dynamic role of microglia and the endocannabinoid system in neuroinflammation. Front. Pharmacol. 12, 806417. doi:10.3389/fphar.2021.806417

Zhang, B., Zhong, Q., Chen, X., Wu, X., Sha, R., Song, G., et al. (2020). Neuroprotective effects of celastrol on transient global cerebral ischemia rats via regulating HMGB1/NF-κB signaling pathway. Front. Neurosci. 14, 847. doi:10.3389/fnins.2020.00847

Zhang, C., Wang, R., Liu, Z., Bunker, E., Lee, S., Giuntini, M., et al. (2019). The plant triterpenoid celastrol blocks PINK1-dependent mitophagy by disrupting PINK1’s association with the mitochondrial protein TOMM20. J. Biol. Chem. 294 (18), 7472–7487. doi:10.1074/jbc.RA118.006506

Zhang, C., Zhao, M., Wang, B., Su, Z., Guo, B., Qin, L., et al. (2021). The Nf2–NLRC3-caspase-1 axis mediates the neuroprotective effects of Celastrol in Parkinson’s disease. Redox Biol. 47, 102134. doi:10.1016/j.redox.2021.102134

Zhang, J., Jiang, Z., Mu, X., Wen, J., Su, Y., and Zhang, L. (2012a). Effect of triptolide on progesterone production from cultured rat granulosa cells. Acta Pharm. Sin. B 12 (4), 1707–1722. doi:10.1016/j.apsb.2012.01.037

Zhang, J., Liu, L., Mu, X., Jiang, Z., and Zhang, L. (2012b). Effect of triptolide on estradiol release from cultured rat granulosa cells. Endocr. J. 59 (6), 473–481. doi:10.1507/endocr.11-0407

Zhang, Y. Q., and Sarge, K. D. (2007). Celastrol inhibits polyglutamine aggregation and toxicity though induction of the heat shock response. J. Mol. Med. 85 (12), 1421–1428. doi:10.1007/s00109-007-0251-9

Zhao, Y., Zhao, H., Lobo, N., Guo, X., Gentleman, S. M., and Ma, D. (2014). Celastrol enhances cell viability and inhibits amyloid-β production induced by lipopolysaccharide in vitro. J. Alzheimer’s Dis. 41 (3), 835–844. doi:10.3233/JAD-131799

Zheng, Y., Zhang, W. J., and Wang, X. M. (2013). Triptolide with potential medicinal value for diseases of the central nervous system. CNS Neurol. Ther. 19 (2), 76–82. doi:10.1111/cns.12039

Zhou, H. F., Liu, X. Y., Niu, D. B., Li, F. Q., He, Q. H., and Wang, X. M. (2005). Triptolide protects dopaminergic neurons from inflammation-mediated damage induced by lipopolysaccharide in vitro. J. Alzheimer’s Dis. 41 (3), 835–844. doi:10.3233/JAD-131799

Zhou, H. F., Niu, D. B., Xue, B., Li, F. Q., Liu, X. Y., He, Q. H., et al. (2003). Triptolide inhibits TNF-alpha, IL-1 beta and NO production in primary microglial cultures. Neuroreport 14 (7), 1091–1095. doi:10.1097/01.wnr.0000073682.00308.47

Zhu, F., Yuan, J., Yang, X., Huang, Y., Jiang, Y., Wang, Y., et al. (2020). Triptolide improves spinal cord injury by promoting autophagy and inhibiting apoptosis. Cell Biol. Int. 44 (3), 785–794. doi:10.1002/cbi.11273